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Cyclooxygenase-2 (COX-2) expression is associated with poor prognosis across a range of human cancers,
including breast. While the contributions of tumor cell-derived COX-2 are well studied, those of the stroma
remain ill-defined. Macrophages, an essential component of the tumor microenvironment, exist within a range
of two polar phenotypes, influenced by signals in their local environment: anti-tumorigenic M1 or pro-
tumorigenic M2. M2-like tumor-associated macrophages (TAM) are positively associated with tumorigenesis.
This thesis investigates the contribution of macrophage COX-2 in two models of HER2/neu-induced
mammary tumorigenesis utilizing mice selectively lacking macrophage COX-2 (COX-2MÃ?KO) and the
contribution of COX-2 derived products in modifying macrophage phenotype in vitro. Finally, a targeted
macrophage COX-2 inhibitor is investigated in vitro and in vivo as a potential cancer therapeutic. Deletion of
macrophage COX-2 led to reduced mammary tumorigenesis coincident with fewer TAMs and reduction in
M2 characteristics of TAM. Further, depletion of CD8+ cytotoxic T lymphocytes (CTLs), but not CD4+ T
helper and regulatory cells, restored tumor growth in COX-2MÃ?KO mice, suggesting enhanced CTL
function caused by reduction in total and M2-like TAM. Investigation of COX-2-mediated polarization of
bone marrow-derived macrophages (BMDM) in vitro revealed paracrine influences of prostaglandin (PG) E2
in modifying polarized macrophage phenotype to more closely resemble TAM. Interestingly, interference
with macrophage COX-2 did not significantly modify BMDM polarization. This suggested that autocrine
COX-2 minimally affects BMDM phenotype, and that polarization of COX-2MÃ?KO BMDM does not
recapitulate reduced M2 characteristics observed in COX-2MÃ?KO TAM. Reconstituted high-density
lipoprotein (rHDL) nanoparticles were utilized as a method to target macrophages in vitro and in vivo. rHDL
conjugated to fluorescent dye DiR revealed efficient incorporation of rHDL nanoparticles with TAM. In
preliminary experiments utilizing rHDL-celecoxib as a targeted macrophage COX-2 inhibitor, marked
suppression of PGD2 and PGE2 generation was evident in lipopolysaccharide (LPS)-stimulated J774A.1 cells.
Importantly, urinary prostaglandin levels were not altered in mice treated with rHDL-celecoxib, suggesting no
systemic inhibition of COX-2 with this targeted approach. These studies provide rationale for targeting
macrophage COX-2 in mammary tumorigenesis and provide essential preliminary experiments in translating
these findings into a potential chemopreventative or chemotherapeutic agent.
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ABSTRACT 
AUGMENTING ANTI-TUMOR IMMUNITY BY TARGETING MACROPHAGE COX-2 IN BREAST CANCER  
 
Edward P. Chen 
Emer M. Smyth 
Cyclooxygenase-2 (COX-2) expression is associated with poor prognosis across a range of human 
cancers, including breast. While the contributions of tumor cell-derived COX-2 are well studied, 
those of the stroma remain ill-defined. Macrophages, an essential component of the tumor 
microenvironment, exist within a range of two polar phenotypes, influenced by signals in their 
local environment: anti-tumorigenic M1 or pro-tumorigenic M2. M2-like tumor-associated 
macrophages (TAM) are positively associated with tumorigenesis. This thesis investigates the 
contribution of macrophage COX-2 in two models of HER2/neu-induced mammary tumorigenesis 
utilizing mice selectively lacking macrophage COX-2 (COX-2MØKO) and the contribution of COX-2 
derived products in modifying macrophage phenotype in vitro. Finally, a targeted macrophage 
COX-2 inhibitor is investigated in vitro and in vivo as a potential cancer therapeutic. Deletion of 
macrophage COX-2 led to reduced mammary tumorigenesis coincident with fewer TAMs and 
reduction in M2 characteristics of TAM. Further, depletion of CD8+ cytotoxic T lymphocytes (CTLs), 
but not CD4+ T helper and regulatory cells, restored tumor growth in COX-2MØKO mice, suggesting 
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enhanced CTL function caused by reduction in total and M2-like TAM. Investigation of COX-2-
mediated polarization of bone marrow-derived macrophages (BMDM) in vitro revealed paracrine 
influences of prostaglandin (PG) E2 in modifying polarized macrophage phenotype to more closely 
resemble TAM. Interestingly, interference with macrophage COX-2 did not significantly modify 
BMDM polarization. This suggested that autocrine COX-2 minimally affects BMDM phenotype, 
and that polarization of COX-2MØKO BMDM does not recapitulate reduced M2 characteristics 
observed in COX-2MØKO TAM. Reconstituted high-density lipoprotein (rHDL) nanoparticles were 
utilized as a method to target macrophages in vitro and in vivo. rHDL conjugated to fluorescent 
dye DiR revealed efficient incorporation of rHDL nanoparticles with TAM. In preliminary 
experiments utilizing rHDL-celecoxib as a targeted macrophage COX-2 inhibitor, marked 
suppression of PGD2 and PGE2 generation was evident in lipopolysaccharide (LPS)-stimulated 
J774A.1 cells. Importantly, urinary prostaglandin levels were not altered in mice treated with 
rHDL-celecoxib, suggesting no systemic inhibition of COX-2 with this targeted approach. These 
studies provide rationale for targeting macrophage COX-2 in mammary tumorigenesis and 
provide essential preliminary experiments in translating these findings into a potential 
chemopreventative or chemotherapeutic agent.  
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CHAPTER 1 : BREAST CANCER AND THE CONTRIBUTION OF COX-2 
1.1 Breast Cancer and the Role of the Tumor Microenvironment 
1.1.1 Breast Cancer and Current Treatment 
Although a decade of significant advances in breast cancer prevention and 
treatment have steadily decreased breast cancer-related mortality (Figure 1-1), breast 
cancer remains the most common non-skin cancer (est. 233,000 new cases in 2014) and 
the second leading cause of cancer deaths among women (est. 40,000 deaths in 2014) in 
the United States (American Cancer Society 2014). Breast cancer is a heterogeneous 
mixture of diseases with varying morphology and malignancy, the majority of which are 
classified by location (ductal versus lobular) and aggressiveness (invasive breast cancer 
versus carcinomas in situ), though several unique forms of breast cancer exist, including 
inflammatory and triple-negative breast cancer. 
Treatment options vary by stage at diagnosis. Standard of care includes local 
control through partial/full mastectomy or radiation therapy with adjuvant or 
neoadjuvant systemic therapy using chemotherapeutic agents, hormone therapy (such 
anti-estrogens or estrogen antagonists), and/or targeted therapies (such as monoclonal 
antibodies). Even with early detection and current treatment options, breast cancer 
remains a significant public health problem. Each treatment option comes with a variety  
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Figure 1-1 Age-adjusted cancer-related mortality rate of women in the US.  
Despite advances in breast cancer detection and treatment, breast cancer remains the second leading cause of cancer-
related deaths among women in the United States. Figure reproduced with permission (American Cancer Society, 2014). 
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of adverse effects. Additionally, more aggressive cancers, such as triple-negative breast 
cancers, which are neither ER (estrogen receptor), PR (progesterone receptor), nor 
HER2/neu positive, create a unique challenge as certain hormone and targeted therapies 
are not efficacious. Finally, lack of complete eradication of the primary disease allows for 
eventual recurrence or distant metastases, and innate or acquired resistance to systemic 
therapies (such as trastuzumab, an anti-HER2/neu antibody) (Rexer and Arteaga 2012) in 
some patients further limits treatment options. Identification of novel therapeutics in the 
treatment of breast cancer as adjuvant treatments that are not subject to the same 
mechanisms of resistance as current therapies, and have a reduced adverse events 
profile, is a current objective of breast cancer research. 
1.1.2 The Tumor Microenvironment 
Solid tumors have two main components: malignant epithelial cells and the 
stroma, or microenvironment, surrounding the tumor cells. The tumor microenvironment 
(TME) consists of extracellular matrix (ECM), signaling molecules such as cytokines and 
growth factors, immune cells, endothelial cells, fibroblasts, and adipocytes (Place, Jin Huh 
et al. 2011, Fang and Declerck 2013). The TME was recognized as being potentially 
involved in tumorigenesis over a century ago (Paget 1989), but after the discovery of the 
first oncogene in 1979 (Oppermann, Levinson et al. 1979) and the first tumor suppressor 
gene in 1986 (Friend, Bernards et al. 1986), a majority of cancer research has focused on 
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genetic mutations in malignant epithelial cells. However, the demonstration that the Rous 
sarcoma virus was unable to establish new tumors in a different microenvironment within 
the same species (Dolberg and Bissell 1984) shifted attention to the TME  (Dvorak 1986, 
van den Hooff 1988). Work over the past ten years has confirmed the TME as a major 
regulator of tumor progression, such that a tumor promoting TME is now considered a 
hallmark of cancer (Hanahan and Weinberg 2011) and the use of a stromal gene 
expression predictive indicator can predict clinical outcome in breast cancer with greater 
accuracy than current prognostic indicators (Finak, Bertos et al. 2008). 
The immune cells of the TME play a vital role in the progression of a tumor to 
malignancy. The TME contains varying proportions of tumor-associated macrophages 
(TAMs), neutrophils, cytotoxic T lymphocytes (CTLs), type 1 and 2 helper T cells (TH1/TH2), 
regulatory T cells (TREGs), natural killer (NK) cells, myeloid-derived suppressor cells 
(MDSCs), and other leukocytes (DeNardo, Barreto et al. 2009). These cells, which may 
migrate to the tumor site or become activated in order to initiate an immune response to 
the tumor, seem to be re-educated by tumor expression of co-inhibitory molecules and 
secretion of type 2 cytokines to support further epithelial cell growth and suppression of 
immunosurveillance (Place, Jin Huh et al. 2011). Indeed, it may be that tumor cells 
promote alternative functions of certain leukocytes, particularly those involved in wound 
healing, development, and inflammation resolution, where suppression of inflammation 
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is desired (Dvorak 1986, Crowther, Brown et al. 2001). One immune component of the 
TME, macrophages, have emerged as critical in mammary tumorigenesis. 
1.1.3 Macrophage Polarization 
Macrophages are highly adaptable cells that elicit both pro- and anti-tumorigenic 
responses (Ding, Nathan et al. 1988, Sica, Schioppa et al. 2006). In the 1970s, it was shown 
that macrophages stimulated by lipopolysaccharide (LPS) could stimulate tumor cell 
apoptosis (Doe and Henson 1978), leading to the general notion that macrophages could 
suppress tumors through the release of reactive nitrogen/oxygen species (RNS/ROS) and 
tumor necrosis factor α (TNFα) (Ding, Nathan et al. 1988). However, in 1992, Gordon and 
colleagues observed that macrophages stimulated with type 2 cytokines, specifically, 
interleukin (IL-) 4, adopted a phenotype that was markedly different from that of 
macrophages stimulated with interferon (IFN) γ or LPS (Stein, Keshav et al. 1992). Thus, 
stimulation with IL-4 failed to induce expression of TNFα, and instead increased 
expression and function of the macrophage mannose receptor (MR), an important 
receptor in phagocytosis of microorganisms (Stein, Keshav et al. 1992). Based on these 
experiments, a spectrum of macrophage polarization was introduced in which 
macrophages stimulated with type 1 cytokines such as TNFα and IFNγ, or activators of 
Toll-like receptor (TLR) 4 like LPS, were termed classically activated, whereas 
macrophages stimulated with type 2 cytokines such as IL-4 and IL-13 were classified as 
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alternatively activated. These macrophages were also termed M1 or M2, respectively, to 
mirror the TH1/TH2 paradigm in T helper cell differentiation. Many markers of M1 and M2 
macrophage polarization exist (Figure 1-2), although their distinct arginine-metabolic 
enzymatic pathways are prototypic. M1 macrophages, which express inducible nitric 
oxide synthase (iNOS), metabolize L-arginine to nitric oxide, generating ROS and other RNS 
that contribute to M1 pro-inflammatory and anti-tumorigenic functions. M2 
macrophages, in contrast, through the actions of arginase-1, metabolize L-arginine into L-
ornithine and putrescine which support epithelial cell proliferation, and importantly, 
deplete the supply of L-arginine available for the production of RNS by other cytotoxic 
cells (Chang, Liao et al. 2001, Rodriguez, Quiceno et al. 2004, Keibel, Singh et al. 2009).  
M1 and M2 macrophages can further be classified by their release of pro-inflammatory 
(e.g. TNFα, IL-12, and IL-1β) or immunosuppressive (e.g. TGFβ and IL-10) cytokines and 
expression of cell surface markers. M1 macrophages express major histocompatibility 
type II molecules (MHCII) which can support development of adaptive immunity towards 
transformed epithelial cells through antigen presentation (Stein, Keshav et al. 1992), 
while M2 macrophage express a number of scavenger receptors which allows for 
scavenging of self-debris produced during a tumor-invoked immune response while 
simultaneously suppressing that immune response (Fairweather and Cihakova 2009). 
Additional differences between the M1 and M2 macrophage phenotypes include 
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Figure 1-2 Examples of macrophage polarization and common M1 and M2 phenotypic markers.  
Macrophages can be polarized to unique phenotypes dependent in response to signals in their immediate 
microenvironment. Macrophage phenotypes extend across a range of functions, the extremes of which are classified 
as M1 and M2. These polarization states are considered anti- and pro-tumorigenic, respectively. Tumor-associated 
macrophages are considered M2-like due to their role in immunosuppression and promotion of angiogenesis and tumor 
growth. Figure reproduced with permission(Biswas and Mantovani, 2010). 
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maintenance of iron homeostasis (Recalcati, Locati et al. 2010) and folate metabolism 
(Puig-Kroger, Sierra-Filardi et al. 2009). The complex nature of macrophage responses to 
signals in their microenvironment and the functional plasticity they display underscores 
the need to investigate the contribution of macrophages to tumorigenesis. 
1.1.4 Phenotype and Function of Tumor-Associated Macrophages 
The M1/M2 macrophage phenotype dichotomy has been useful in characterizing 
macrophages polarized in vitro as models of disease microenvironments. In reality, TAMs 
have several unique characteristics that cannot be strictly defined as M1 or M2. Genetic 
and phenotypic profiling of TAMs have encouraged their classification as M2-like due to 
their low expression of IL-12, high expression of IL-10 (Mantovani, Sozzani et al. 2002), 
and, with elevated arginase-1, a reduced capacity to generate ROS/RNS (Movahedi, Laoui 
et al. 2010). In addition, distinct subsets of TAMs induce angiogenesis through expression 
of vascular endothelial growth factors (VEGFs), epidermal growth factor (EGF), and IL-8 
(Mantovani, Sozzani et al. 2002, Lin, Li et al. 2006, Biswas and Mantovani 2010), and 
matrix remodeling through release of matrix metalloproteases (MMP) 2, and urokinase 
plasminogen activator (Hildenbrand, Dilger et al. 1995, Eubank, Galloway et al. 2003, 
Mantovani, Schioppa et al. 2006). However, in contrast to the “standard” M2 phenotype, 
TAMs also produce M1 cytokines TNFα and IL-6 (Ikemoto, Yoshida et al. 2003). 
Additionally, they express several TH1 recruiting chemokines, such as CXCL9 and CXCL10 
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(Biswas, Gangi et al. 2006), and can express iNOS, which was associated with enhanced T 
cell suppression (Kusmartsev and Gabrilovich 2005). Importantly, TAMs do not express all 
markers simultaneously, and as such, represent a heterogeneous population of 
macrophages polarized by their immediate microenvironment in order to perform 
specific functions within distinct regions of the tumor (Van Ginderachter, Movahedi et al. 
2006), such as promotion of angiogenesis, dampening of immune function, or support of 
invasion through ECM remodeling.  
The observation that TAM phenotype is reprogrammable (Ostrand-Rosenberg 
2008, Stout, Watkins et al. 2009, Biswas and Mantovani 2010) has focused attention on 
TAM-targeted therapies that may, through stimulation with certain cytokines, activation 
of specific receptors, or blockade of signaling pathways involved in polarization, promote 
M1 phenotypic dominance over M2 (Kortylewski, Kujawski et al. 2005, Buhtoiarov, Lum 
et al. 2006, Duluc, Corvaisier et al. 2009), thereby enhancing anti-tumor activity in 
macrophages. 
1.1.5 TAM Regulation of Mammary Tumorigenesis 
Considering their tumor-promoting effects, it is unsurprising that TAM density in 
cancer is correlated with poor prognosis in over 80% of clinical studies (Lin and Pollard 
2004) and is associated with higher histological tumor grade, low hormone receptor 
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expression, and enhanced tumor mitosis in breast cancer (Volodko, Reiner et al. 1998).  
Animal studies investigating TAM support of tumorigenesis corroborate the 
clinical association of TAM density and poor prognosis in cancer. Csfop/Csfop mice, which 
bear a natural null recessive mutation in the colony-stimulating factor-1 (CSF-1) gene, 
depleting the systemic macrophage population, or mice in which macrophages are 
depleted with liposome-encapsulated clodronate, showed reduced angiogenesis and 
histological progression to malignancy in spontaneous tumors expressing the Polyoma 
middle T oncogene (PyMT) under the control of the mouse mammary tumor virus 
(MMTV), which directs oncogene expression to mammary epithelial cells (MEC) (Lin, 
Nguyen et al. 2001, Lin, Li et al. 2006, Qian, Deng et al. 2009). Expression levels of CSF-1, 
a primary macrophage growth factor and chemokine, is also linked to poor prognosis in 
breast cancer (Kacinski 1997, Beck, Espinosa et al. 2009) and interference with CSF-1 
through the use of antisense oligonucleotides or small interfering RNA (siRNA) suppressed 
growth of mammary tumor xenografts (Aharinejad, Paulus et al. 2004). Studies of CSF-1 
depletion or interference, or CSF-1 receptor antagonism, in mouse models of other 
cancers have yielded similar results (Nowicki, Szenajch et al. 1996, Priceman, Sung et al. 
2010). Selective destruction of systemic macrophages, through treatment with a 
legumain-based DNA vaccine or an attenuated Shignella flexneri, has also shown 
promising outcomes, resulting in reduced tumor growth, metastasis, and even tumor 
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regression (Luo, Zhou et al. 2006, Galmbacher, Heisig et al. 2010). 
 The plasticity and heterogeneity of macrophages open potential treatment 
options in re-education of TAMs from pro-tumorigenic to anti-tumorigenic (Stout, 
Watkins et al. 2009). In fact, in certain cancers TAM density is correlated with good 
prognosis (Lewis and Pollard 2006), indicating that within the appropriate 
microenvironment, TAM may be inherently anti-tumorigenic (Table 1-1). Multiple in vitro 
studies of isolated macrophages and TAMs have shown that re-polarization can induce 
epigenetic changes that sustain the polarization state for subsequent generations 
(Ivashkiv 2013). Further, attempts to reprogram TAMs in vivo have been successful. Thus, 
treatment of tumor bearing mice with liposome-encapsulating IL-12 and granulocyte-
macrophage CSF (GM-CSF) led to a cytotoxic response and tumor regression that was 
dependent on type 1 cells such as CTLs and NK cells (Hill, Conway et al. 2002, Tsung, Dolan 
et al. 2002). In another study, knockout (KO) of p50, a subunit of NF-κB, showed a class 
switching of TAM towards an M1 phenotype and reduced transplanted tumor growth 
(Saccani, Schioppa et al. 2006). Adoptive transfer of RBP-/- monocytes, which are deficient 
in Notch signaling and have reduced production of the M1 cytokines IFNγ, IL-12, and 
TNFα, increased tumor volume and weight in Lewis lung carcinoma and B16 melanoma 
injected mice (Wang, He et al. 2010). Additionally, injection with a CpG oligonucleotide as 
an activator of TLR9, simultaneously with anti-IL-10 treatment, switched macrophage 
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Table 1-1 TAMs Correlate with Prognosis in Different Cancers.  
High numbers of TAM correlate with poor prognosis in breast and many other cancers. However, in certain cancers, 
high numbers of TAM correlate with good prognosis. Reproduced with permission and modified (Lewis and Pollard, 
2006).  
High Numbers of TAMs Correlate with Survival in 
Different Cancers 
Favorable Prognosis Poor Prognosis 
Stomach Breast*,+ 
Colorectal Prostate* 
Melanoma Endometrial* 
 Bladder*,+ 
 Kidney* 
 Esophageal 
 Superficial+ 
 Squamous cell carcinoma* 
 Malignant uveal melanoma* 
 Follicular lymphoma 
*Correlation with increase tumor angiogenesis 
+Correlation with increased involvement of local lymph nodes. No correlation with 
survival was found in colon carcinoma, high-grade astrocytomas, lung carcinoma, or 
cervical carcinoma 
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Figure 1-3 Overview of eicosanoid synthesis, degradation, and transport.  
COX-1 and -2 are enzymes responsible for the metabolism of arachidonic acid into PGH2, which is further metabolized 
by downstream prostaglandin synthases to PGE2, PGF2α, PGD2, PGI2, and TxA2. These prostanoids act on specific 
prostanoid receptors, EP1-4, FP, DP1-2, IP, and TP, respectively. 15-PGDH carries out the first step in degradation of 
PGE2, which has established pro-tumorigenic and immunomodulatory effects while steady state extracellular levels of 
PGE2 are maintained by efflux protein MRP4 and influx protein PGT. Arachidonic acid may be metabolized through 
other eicosanoid synthesis pathways to, for example, the leukotrienes, HETEs, EETs, HPETEs, and oxo-ETEs, which may 
be altered through substrate shunting during COX inhibition. Reproduced with permission (Wang and Dubois, 2010). 
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phenotype from M2 to M1, as evident by enhanced iNOS, TNFα, and IL-12 expression by 
TAMs (Guiducci, Vicari et al. 2005) and this was coincident with rejection of transplanted 
mammary tumor carcinoma cell lines TSA and 4T1. Together these studies provide 
substantial evidence that therapies targeting macrophage phenotype may be of 
therapeutic benefit in breast or other cancers. 
1.2 Targeting Cyclooxygenase-2 in Breast Cancer 
1.2.1 Cyclooxygenases, Prostaglandins, and Other Eicosanoids 
Cyclooxygenase (COX) is an enzyme responsible for the metabolism of arachidonic 
acid (AA), released from cell membranes by the action of cytosolic phospholipase A2, to 
prostaglandin (PG) H2. Two isoforms of COX exists in human and mice: COX-1, which is 
predominantly responsible for constitutive generation of prostaglandins, and COX-2, 
which is mainly induced in response to a variety of inflammatory and growth signals 
(Smyth, Grosser et al. 2009, Wang and Dubois 2010). COX-1/COX-2, also known as 
prostaglandin-endoperoxide synthase 1/2, catalyzes a two-step process in which AA is 
first converted into an unstable cyclooxygenated species, PGG2, and then reduced 
through peroxidation to form stable PGH2. PGH2 is further metabolized by downstream 
prostaglandin synthases to PGD2, PGE2, PGI2 (also known as prostacyclin). PGF2α, and TxA2 
(also known as thromboxane), collectively termed the prostanoids, a family of lipid 
mediators with diverse and widespread biological functions.  The prostanoids act on 
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specific G-protein coupled receptors (respectively, DP1-2, EP1-4, IP, FP, and TP) 
modulating physiological and pathological processes. Control of these diverse lipid 
pathways is directed through cell and context specific regulation of differential COX 
isoform and PG synthase expression and function, as well as PG receptor expression.  
Importantly, AA also can be metabolized through non-COX pathways, including 
metabolism by lipooxygenases and P450 enzymes (Wang and Dubois 2010), leading to 
generation of other eicosanoids, such as the leukotrienes, hydroxyeicosatetraenoic acids 
(HETEs), and eicosatetraenoic acids (EETs) (Figure 1-3). AA metabolism through these 
pathways can also contribute to human pathologies, including cancer, and may be 
particularly relevant during COX inhibition when redirection of AA modifies the local lipid 
profile. 
1.2.2 COX-2 and PGE2 in Breast and Other Cancers 
Multiple human and animal studies report COX-2 overexpression in breast cancer 
(Harris 2009, Chen and Smyth 2011). Indeed, targeted mammary epithelial 
overexpression of COX-2 using the MMTV promoter to control expression, was sufficient 
to cause mammary tumorigenesis in multiparous mice (Liu, Chang et al. 2001). This was 
dependent on PGE2 signaling through the EP2 receptor (Chang, Ai et al. 2005) with 
upregulation of P450 aromatase (Subbaramaiah, Howe et al. 2006), which could be 
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reversed by COX-2 inhibition. Additionally, selective COX-2 inhibition reduced mammary 
tumorigenesis in a 7,12-dimethylbenzanthracene (DMBA) carcinogen-induced model of 
rat tumorigenesis (Harris, Alshafie et al. 2000, Kubatka, Ahlers et al. 2003) while in mice, 
COX-2 inhibition reduced disease in spontaneous HER2/neu- and LLC xenograft models 
(Lanza-Jacoby, Miller et al. 2003, Qadri, Wang et al. 2005). Further, global KO of COX-2 
reduced size and multiplicity in a HER2/neu model of mammary tumorigenesis with 
concurrent reduction in tumor vessel density and expression of angiogenic markers 
(Howe, Chang et al. 2005). Notably, the molecular mechanisms determining reduced 
tumorigenesis are ill-defined across many studies involving COX-2 pathway disruption, 
with scant attention generally paid to the tumor stroma and immune microenvironment. 
PGE2 is the dominant pro-tumor product of COX-2 (Wang and Dubois 2010). COX-
derived PGH2 is converted to PGE2 through the actions of microsomal prostaglandin E 
synthase (mPGES) 1 and 2 and cytosolic prostaglandin E synthase (cPGES). Similar to COX-
2, mPGES-1 is induced by a variety of stimuli and is the dominant E synthase in tumors 
(Kamei, Murakami et al. 2003) and functional coupling of COX-2 and mPGES-1 has been 
reported, while cPGES couples to COX-1 (Murakami, Naraba et al. 2000, Tanioka, Nakatani 
et al. 2000). Though less well studied, it appears that both COX-1 and COX-2 can couple 
with mPGES-2 (Wang and Dubois 2010). PGE2 acts through four functionally distinct G 
protein-coupled receptors, EP1, EP2, EP3, and EP4. EP1 is coupled to Gi, EP3 is coupled to 
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Gq, while EP2 and 4 are coupled to Gs. PGE2 has been studied thoroughly as a promoter 
of tumorigenesis (Greenhough, Smartt et al. 2009). PGE2 signaling can suppress glycogen 
synthase kinase (GSK) 3β, which is a component of the β-catenin destruction complex 
(Castellone, Teramoto et al. 2005). The failure of GSK3β to complex with Axin and 
adenomatosis polyposis coli allows for accumulation of the β-catenin/T cell factor 4 
complex, leading to transactivation of the peroxisome proliferator-activated receptor 
(PPAR) δ and transcription of pro-tumor genes, such as MMPs, the uPA receptor, and 
cyclin D1 (Wang, Wang et al. 2004). PGE2 is also known to transactivate the EGF receptor 
(EGFR), downstream Ras-MAPK pathways, and induce anti-apoptotic protein Bcl-2 
(Sheng, Shao et al. 1998, Pai, Soreghan et al. 2002, Wang, Buchanan et al. 2005). 
Additionally, studies have implicated PGE2 signaling with enhanced angiogenesis, which 
may occur through EP3-mediated enhanced transcription of VEGF and/or its receptors 
through ERK/JNK pathways (Pai, Szabo et al. 2001, Amano, Hayashi et al. 2003, Amano, 
Ito et al. 2009). 
Prostaglandin signaling through cell membrane receptors is conditioned by 
synthesis, transport, and degradation of associated prostaglandins. Solute carrier organic 
anion transporter 2A1, also known as the prostaglandin transporter (PGT) is responsible 
for uptake of PGE2, as well as PGD2 and PGF2α, from the extracellular space into the cytosol 
(Holla, Backlund et al. 2008). Multidrug resistance protein (MRP) 4 can transport PGE2 and 
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PGF2α from the intracellular to the extracellular space, although this process can also 
occur through simple diffusion (Reid, Wielinga et al. 2003). 15-hydroxyprostaglandin 
dehydrogenase (15-PGDH) is the catalyzing enzyme in the first step of PGE2 degradation 
into its inactive 13,14-dihydro-15-keto-metabolite and thus contributes to lower overall 
PGE2 levels. Human colorectal cancers are associated with lower expression of 15-PGDH 
and PGT, which would lead to increased PGE2 available in the extracellular space 
(Backlund, Mann et al. 2005, Mann, Backlund et al. 2006), as compared to normal colon 
tissue. Enhanced MRP4 expression was also observed in these tissues. These studies 
highlight the importance of considering contributors to steady state prostaglandin levels. 
Studies have generally focused on PGE2 as the dominant prostaglandin mediator 
in tumorigenesis, progression, and metastasis. However, other prostanoids may also 
contribute. TxA2 enhanced angiogenesis in one model of tumorigenesis (Pradono, Tazawa 
et al. 2002), while PGD2 may be either pro- or anti-tumorigenic dependent on DP1/DP2 
receptor expression (Yoshida, Ohki et al. 1998, Murata, Aritake et al. 2011). It is 
important, therefore, to consider the full complement of COX products, as well as 
substrate shunting to alternative pathways (e.g. the lipooxygenases), when individual 
components of the arachidonic acid cascade are modified. 
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1.2.3 PGE2-dependent Immunomodulation in Cancer 
PGE2 is associated with a suppressed M1 response, including reduction of M1 
polarization markers and restraint of type 1 cytokine production. TAMs isolated from 
human ovarian cancers showed decreased NF-κB activation and depressed release of M1 
cytokines after treatment with exogenous PGE2, which models the paracrine involvement 
of COX-2 derived PGE2 (Saccani, Schioppa et al. 2006). Additionally, PGE2 treatment of 
macrophages suppressed release of several M1 cytokines, such as IL-1β (Knudsen, 
Dinarello et al. 1986), TNFα, and IL-6 (Bailly, Ferrua et al. 1990) in LPS-stimulated human 
peripheral blood monocytes, IL-8 in LPS-stimulated human alveolar macrophages 
(Standiford, Kunkel et al. 1992), and IL-6 and TNFα in LPS-stimulated murine residential 
peritoneal macrophages (RPMs) (Strassmann, Patil-Koota et al. 1994). Similarly, J774 cells 
stimulated with LPS showed reduced expression of M1 marker iNOS after PGE2 treatment 
(D'Acquisto, Sautebin et al. 1998). These effects seemed to be mediated via EP2/EP4-
signaling through elevated cyclic AMP (Standiford, Kunkel et al. 1992). PGE2 has also been 
shown to enhance production of M2 cytokine IL-10 and M2 marker arginase-1 in both 
murine RPMs (Strassmann, Patil-Koota et al. 1994) and bone marrow-derived 
macrophages (BMDM) (Wu, Llewellyn et al. 2010). These studies indicate that PGE2 may 
act in a paracrine manner to favor the pro-tumor M2 macrophage phenotype with co-
incident suppression of anti-tumor M1 function. 
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The distinct autocrine influence of macrophage-derived PGE2 has been studied in 
vitro and in a transplant setting. Briefly, COX-2 inhibition switched bone marrow cell 
differentiation towards an F4/80+CD11c+ antigen-presenting cell (APC) phenotype, 
indicative of an M1 macrophage phenotype (Eruslanov, Daurkin et al. 2010). In the same 
study, tumor cell-conditioned medium diverted bone marrow cell differentiation away 
from the APC phenotype with an increase in 15-PGDH/PGT and decrease in MRP4 
expression, suggesting that the COX-2-PGE2 pathway was an integral autocrine mediator 
in macrophage polarization. Interestingly, a dual mPGES-1/5-LO inhibitor (CAY10589) did 
not recapitulate the phenotype observed with a COX-2 inhibitor, suggesting that 
degradation enzymes, or other COX-2-derived products, may play a role (Eruslanov, 
Kaliberov et al. 2009). Additionally, enhanced PGE2 degradation, through induction of the 
15-PGDH gene, supported APC phenotype differentiation with a marked reduction in M2 
cytokines IL-10 and IL-13 in a xenograft model of colon cancer (Eruslanov, Kaliberov et al. 
2009). More recent studies have recapitulated these findings in both humans and murine 
macrophages (Nakanishi, Nakatsuji et al. 2011, Na, Yoon et al. 2013). 
1.2.4 NSAIDs and the Limitations of COX-2 as a Therapeutic Target 
The studies discussed above provide strong rationale for the use of COX-2 
inhibitors in prevention or treatment of cancer. Non-steroidal anti-inflammatory drugs 
(NSAIDs) are a class of drugs that inhibit COX function. As the name suggests, these drugs 
20 
 
  
are alternatives to steroids that provide anti-inflammatory, anti-pyretic, and analgesic 
effects, reflecting the established functions of prostanoids in inflammation, fever, and 
pain. NSAIDs currently available for over-the-counter use include ibuprofen and 
naproxen, and non-selectively inhibit COX-1 and COX-2 enzymes in a reversible manner. 
Aspirin, which is also a NSAID, irreversibly inhibits COX-1 and COX-2 function through 
acetylation of Ser 530 or Ser 516, respectively, thereby blocking the active enzymatic 
sites. A meta-analysis of chemoprevention studies revealed reduced risk of breast, lung, 
prostate, and colon cancers with non-selective NSAID treatment (Harris 2009). The use of 
aspirin as a chemopreventative agent is promising but complex – the Nurses’ Health Study 
found a reduced risk of breast cancer mortality and distant recurrence associated with 
daily aspirin use (Holmes, Chen et al. 2010), but the larger Women’s Health Study found 
no effect on breast cancer risk after every other day low dose aspirin (Cook, Lee et al. 
2005). Other studies have had varying results (Table 1-2) (Lazzeroni, Petrera et al. 2013). 
Reductions in breast cancer mortality with aspirin may be due, at least in part, to the anti-
platelet effect of aspirin reducing the risk of cancer-associated thrombosis, although the 
pro-tumor effects of platelets, as well as potential COX-independent effects of aspirin, 
require further study.  
A major adverse effect of NSAID use is gastrointestinal (GI) toxicity, which is 
attributed to reduced prostaglandin-mediated maintenance of the GI tract. Under  
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Table 1-2 Epidemiologic studies on breast cancer risk and aspirin use.  
Though aspirin use is associated with reduced risk in certain cancers, reports of benefit in breast cancer is inconsistent. 
Early reports indicate that breast cancer-related mortality and distant recurrence are reduced with aspirin use, although 
later studies found no association with improved survival and the Women’s Health Study found no effect on breast 
cancer risk from associated with aspirin use. Reproduced with permission (Lazzeroni, Petrera et al, 2013).  
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the assumption that the anti-inflammatory effects of NSAIDs resulted from inhibition of 
the inducible COX-2 enzyme and GI toxicity due to inhibition of COX-1, great effort was 
dedicated to the development of a new class of COX-2 selective NSAIDs. Case and 
population control studies showed not only a reduced risk of breast (Harris, Beebe-Donk 
et al. 2006) and other cancers (Harris 2009), but also a reduced adverse events profile 
related to GI toxicity (Laine 2002, Rostom, Muir et al. 2007). However, enthusiasm for 
these drugs has been dampened by the emergence of increased cardiovascular risk 
(Grosser, Fries et al. 2006, Grosser, Yu et al. 2010). The mechanism that underlies 
increased cardiovascular toxicity has been elucidated, and is attributed to the loss of COX-
2-derived PGI2 and its associated anti-thrombotic and cardioprotective benefits without 
restriction of thrombogenic COX-1-derived TxA2 in platelets. Furthermore, in a recent 
meta-analysis, a similar GI risk was reported for COX-2 selective compared to COX-1/2 
non-selective NSAIDs (CNT Collaboration, 2013). These studies limit the use of COX-2 
inhibitors as a long-term systemic chemopreventative or chemotherapeutic agent and 
raise important questions about targeting COX-2 inhibitor therapies to tumors, thereby 
avoiding or limiting systemic side effects. 
1.2.5 Deletion of Mammary Epithelial COX-2 Alters TAM Phenotype 
To investigate the contribution of tumor cell COX-2 to mammary tumor 
progression, we engineered mice with selective deletion of COX-2 from the mammary 
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epithelium (COX-2MECKO) across two models of mammary tumorigenesis (Markosyan, 
Chen et al. 2011, Markosyan, Chen et al. 2013). Deletion of COX-2 from tumor cells was 
sufficient to reduce tumorigenesis as indicated by reduced tumor onset in both 
carcinogen- (medoxyprogesterone implants with oral administration of DMBA) and 
oncogene-induced (HER2/neu) models of mammary tumorigenesis (Figure 1-4A,B). 
Additionally, in the HER2/neu model, COX-2MECKO mice had fewer tumors per animal 
compared to wild type (WT) mice (Figure 1-4C). 
Interestingly, reduced tumorigenesis in both tumor models was coincident with a shift in 
the tumor microenvironment. In the DMBA model, increased expression of CD45, a 
leukocyte marker, and F4/80, a macrophage marker, was evident in tumors from COX-
2MECKO mice (Figure 1-5A). The latter was somewhat surprising, given that increased 
TAMs are typically associated with enhanced tumor progression (as mentioned above). 
However, in COX-2MECKO mice, TAMs showed higher expression of several M1 markers, 
including CD86, TNFα, and iNOS (Figure 1-5B) with no change in M2 markers (Figure 1-
5C). This suggested that the increase in TAMs was due elevated anti-tumorigenic M1 
macrophages, which delayed tumor progression. In concordance with a shift towards type 
1 immune function in COX-2MECKO tumors, expression of CD2, a marker of NK cells, was 
increased, and F4/80 correlated strongly with the anti-tumor TH1 lymphocyte marker 
TIM3 in COX-2MECKO but not WT tumors (Figure 1-6). In the HER2/neu oncogene model,  
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Figure 1-4 Deletion of mammary epithelial cell COX-2 reduces tumorigenesis. 
Deletion of COX-2 specifically from mammary epithelial cells (COX-2MECKO mice) delayed tumor onset in (A) DMBA-
induced and (B) MMTV-neu-induced models of mammary tumorigenesis. Additionally, (C) MEC COX-2 deletion resulted 
in fewer MMTV-neu induced tumors per animal. Reproduced with permission (Markosyan, Chen et al 2011; Markosyan, 
Chen et al 2013). 
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Figure 1-5 COX-2MECKO mice had an enhanced type 1 immune response.  
In the carcinogen-induced model, (A) expression of CD2, a marker for natural killer cells, was increased in COX-2MECKO 
tumors. (B) Expression of TIM3, a TH1 lymphocyte marker, strongly and positively correlated with F4/80 expression in 
COX-2MECKO, but not WT tumors. Reproduced with permission (Markosyan, Chen et al, 2011). 
 
Figure 1-6 Augmented M1 macrophage infiltration in COX-2MECKO tumors. 
In the carcinogen-induced model, COX-2MECKO tumors had (A) enhanced expression of the leukocyte marker CD45 and 
macrophage marker F4/80. This was coincident with (B) increased expression of several M1 macrophage phenotypic 
markers with (C) no change in expression of M2 macrophage markers. Reproduced with permission (Markosyan, Chen 
et al 2011). 
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reduced angiogenesis (Figure 1-7) was coincident with a similar shift to an enhanced type 
1 immune response, with increased CD3+CD4+ helper T cells and CD3+CD8+ CTLs observed 
in COX-2MECKO tumors (Figure 1-8A). Additionally, CD3-CD8+ cells, which encompass NK 
cells and dendritic cells, were also increased (Figure 1-8B). Positive CD45 selection of 
tumor cells revealed a higher Tbet (TH1 marker) to Gata3 (TH2 marker) ratio (Figure 1-8C), 
providing evidence that the increase in helper T cells reflected an increase in TH1 cells 
promoting a type 1 response. In this model, though no change was observed in M1 
macrophage markers, COX-2MECKO tumor expression of M2 macrophage marker RELMα 
was decreased in leukocytes (CD45-enriched cells) as compared to WT (Figure 1-8D). 
These studies highlight the individual contribution of COX-2 in one tumor component, the 
malignant epithelial cell, to mammary tumor progression and the microenvironmental 
immune response and provide rationale for targeted therapeutics that can activate an 
anti-tumorigenic TME response. 
1.3 Aims of Thesis 
1.3.1 The Contribution of Macrophage COX-2 to Mammary Tumorigenesis 
COX-2 and macrophages have both been independently associated with enhanced 
disease in breast cancer (Chen and Smyth 2011). Though a number of studies have 
suggested that COX-2 expressed by macrophages may support tumor-promoting 
characteristics (Nakanishi, Nakatsuji et al. 2011, Na, Yoon et al. 2013), the specific 
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Figure 1-7 COX-2MECKO mice tumors have reduced angiogenesis.  
In the oncogene-induced model, COX-2MECKO tumors have (A) reduced expression of several markers of tumor 
angiogenesis and have (B) reduced immunostaining for CD31 as a marker of vascular endothelium. Reproduced with 
permission (Markosyan, Chen et al 2013). 
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Figure 1-8 CTL, TH1, and NK cells were increased, and M2 tumor-associated macrophages decreased, in COX-2MECKO 
mice.  
In spontaneous COX-2MECKO tumors, the (A) the proportion of CD4+ and CD8+ T cells, as a proportion of all CD3+ T cells, 
was increased in COX-2MECKO tumors, as was the (B) CD8+CD3- population, which encompasses natural killer and 
dendritic cells. (C) COX-2MECKO tumors had a higher Tbet:Gata3 ratio, indicating an increase in the amount of TH1 cells 
versus TH2 cells. (D) COX-2MECKO tumors had reduced expression of RETNLA (RELMα), an M2 macrophage marker, as 
compared to WT tumors. Reproduced with permission (Markosyan, Chen et al 2013). 
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contribution of macrophage COX-2 to mammary tumorigenesis in vivo is not well defined. 
In the first aim, COX-2 was specifically deleted in macrophages using Cre-Lox 
recombination, and the impact on mammary tumorigenesis studied in two mouse models 
of HER2/neu-driven disease. These studies sought to establish whether and how targeting 
COX-2 in an important stromal component of mammary tumors, TAMs, can alter 
tumorigenesis.  
1.3.2 Autocrine and Paracrine Influences of COX-2 Products to Macrophage Phenotype 
Macrophages are a versatile component of innate immunity that play vital roles in 
both pathological and physiological states (Mantovani, Sozzani et al. 2002, Duluc, 
Corvaisier et al. 2009, Sica and Mantovani 2012). Depending on signals in the extracellular 
environment, macrophages display a range of phenotypes, the extremes of which are 
designated M1 and M2, and typically considered anti-tumorigenic and pro-tumorigenic, 
respectively. Previous reports have shown a critical role of PGE2 in mediating the 
inflammatory characteristics of LPS-stimulated macrophages, which resemble the M1 
phenotype (Knudsen, Dinarello et al. 1986, Bailly, Ferrua et al. 1990, Chen and Smyth 
2011), while pharmacological COX-2 inhibition has been associated with a decreased 
expression of M2 markers in macrophages (Eruslanov, Daurkin et al. 2010, Na, Yoon et al. 
2013). In this aim, the contribution of autocrine and paracrine-derived COX-2 products 
was investigated in vitro in the context of M1 and M2 macrophage polarization though 
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pharmacological inhibition and genetic deletion of macrophage COX-2, and addition of 
exogenous prostaglandins. These studies sought to explore the complex contribution of 
COX-2, from various sources, in modifying macrophage phenotype. 
1.3.3 Development of a Potential Macrophage COX-2 Nanotherapeutic 
The ultimate goal of these studies is improved options in the prevention and 
treatment of breast cancer. The clinical use of systemic selective COX-2, particularly for 
chronic treatment, is limited by unacceptable cardiovascular side effects arising from 
collateral, and clinically unnecessary, suppression of the anti-thrombotic and 
cardioprotective PGI2 in the vascular endothelium (Grosser, Fries et al. 2006, Grosser, Yu 
et al. 2010). Nanoparticle technology can be used to selectively target COX-2 inhibitors to 
macrophages, an approach that could provide, or even increase, therapeutic benefit, 
while avoiding unwanted systemic effects. The larger payload associated with 
nanotherapeutic drug delivery may also allow for reduced dosage, further limiting 
adverse events, or enhanced efficacy. Reconstituted high-density lipoprotein (rHDL) 
nanoparticles have been shown to efficiently incorporate with macrophages in complex 
diseased tissues (Cormode, Skajaa et al. 2008, Duivenvoorden, Tang et al. 2013). In 
collaboration with Drs David Cormode (U Penn), Willem Mulder (Mount Sinai), and 
colleagues, this aim presents preliminary data investigating rHDL-conjugated celecoxib 
and its effectiveness for targeted inhibition of macrophage COX-2.  
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CHAPTER 2 : DELETION OF MACROPHAGE COX-2 IN HER2/NEU-MODELS 
OF MAMMARY TUMORIGENESIS 
2.1 Introduction 
COX-2, the primarily inducible form of cyclooxygenase enzyme, converts 
arachidonic acid into the prostaglandins and is associated with poor prognosis across a 
wide range of cancers, including breast (Harris 2009). The inhibition of COX-2 in mice, 
either pharmacologically or through gene deletion, suppresses mammary tumorigenesis 
(Howe, Subbaramaiah et al. 2002, Lanza-Jacoby, Miller et al. 2003, Howe, Chang et al. 
2005). Importantly, COX-2 has been shown to modulate macrophage polarization in vitro 
and suppress the antigen-presenting phenotype prototypic of anti-tumorigenic M1 
macrophages (Eruslanov, Daurkin et al. 2010). TAMs, which have several characteristics 
similar to pro-tumorigenic M2 macrophages, can influence the function and survival CTLs, 
a major effector cell in tumor immune destruction, through depletion of arginine, which 
CTLs utilize to generate cytotoxic RNS (Chang, Liao et al. 2001), and cell surface expression 
of T cell co-inhibitory molecules (DeNardo, Brennan et al. 2011). TAMs, which respond to 
tumor-produced CSF-1 for trafficking to the tumor site and growth promotion, can also 
encourage tumor growth through secretion of epidermal growth factor (EGF), which 
enhances tumor proliferation (Hernandez, Smirnova et al. 2009). This creates a critical 
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paracrine loop in which TAMs and tumor cells promote each other’s survival. 
HER2 (human epidermal growth factor receptor), also known as ErbB2 or neu, is a 
receptor tyrosine kinase (RTK) related to the EGF receptor family that is overexpressed in 
20-30% of breast cancers (Ursini-Siegel, Schade et al. 2007). HER2 lacks a ligand binding 
domain but acts as a high affinity co-receptor for other HER family RTKs (Barros, Powe et 
al. 2010). Its overexpression is correlated with poor prognosis in human breast cancers, 
and treatment with trastuzumab, a monoclonal antibody against HER2, prolongs disease-
free survival in breast cancer patients (Rexer and Arteaga 2012). Mice that are transgenic 
for an activated form of rat neu, under the control of MMTV to direct mammary epithelial 
expression, develop tumors within 3 months, suggesting that overexpression of 
HER2/neu is sufficient, or requires few activating events, for progression to malignancy 
(Muller, Sinn et al. 1988). Overexpression in human breast cancers are likely due to gene 
overamplification or alternative splicing that allows for homodimerization (Reese and 
Slamon 1997). Signaling through HER2 leads to activation of Ras-MAPK signaling, 
increasing expression of proliferative transcription factors such as c-fos, c-myc, and c-jun 
(Lewin 1991, Mansour, Matten et al. 1994). HER2 also signals through PI3K-Akt, which 
increases expression of CyclinD1 and inhibits p27Kip1, disrupting cell cycle control and 
inhibiting apoptosis (Le, Claret et al. 2003). HER2 overexpression is associated with 
enhanced angiogenesis and invasion through increasing VEGF and tumor growth factor 
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(TGF) β, respectively (Yen, You et al. 2000, Ueda, Wang et al. 2004). Given the histological 
and genetic (Andrechek, Laing et al. 2003) similarities between transgenic HER2/neu 
murine tumors and human HER2/neu overexpressing breast cancer, genetic models of 
HER2-induced disease can be useful and relevant tools to study mammary tumorigenesis. 
The studies that follow employ Cre/lox recombination technology to achieve 
targeted deletion of COX-2 in specific cellular subsets. Cre/lox recombination was first 
described in 1995 (Kuhn, Schwenk et al. 1995), where Cre recombinase, under the control 
of an IFN-responsive promoter, was used to conditionally excise DNA polymerase β by 
flanking the gene target with loxP recognition sites (“flox”). Since then, a number of 
promoters have been utilized to control Cre recombinase expression to conditional or 
cell-specific transcription, and a number of floxed gene deletion studies have been 
reported. Cre recombinase, under the control of the lysozyme M promoter (LysM-Cre) 
directs Cre expression to a subset of myeloid-derived cells, including monocytes, 
macrophages, neutrophils, and certain DCs (Clausen, Burkhardt et al. 1999). FitzGerald 
and colleagues developed a mouse line in which the active site of COX-2 is floxed (COX-
2flox, see below), and have characterized COX-2flox/flox mice crossed with LysM-Cre (Hui, 
Ricciotti et al. 2010). The primary impact of COX-2 deletion in this model was ablation of 
prostanoid production by macrophages (Figure 2-1), leading to reduced  
atherogenesis in hyperlipidemic mice. In the study outlined in this Chapter, this model of 
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Figure 2-1 Prostanoid production after macrophage COX-2 deletion.  
(A) LPS-stimulated production of PGE2, TxA2, PGI2, and PGD2 in cultured residential peritoneal macrophage supernatants 
was ablated in COX-2MØKO mice. Additionally, (B) Urinary prostanoid metabolite levels were significantly reduced in 
LPS-stimulated COX-2MØKO mice. Depression prostanoid formation differed dependent on gender, with significant 
depression in all prostanoids apparent in female COX-2MØKO mice. Reproduced with permission (Hui, Ricciotti 2010). 
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macrophage COX-2 deletion was utilized to study the role of macrophage COX-2 in 
mammary tumorigenesis. 
2.2 Experimental Procedures 
2.2.1 Mouse Background and Genotypes 
 Mouse experiments were conducted in accordance with NIH regulations and were 
approved by the Institutional Animal Care and Use Committee of the University of 
Pennsylvania. 
 COX-2flox/flox mice on the C57/BL6 background have introns 5 and 8 of the COX-2 
gene flanked by loxP sites (“flox”) and have been previously described (Ishikawa and 
Herschman 2006). COX-2flox/flox mice were fully backcrossed to the FVB/N background (>9 
generations) and are denoted as WT mice. Subsequently, WT mice were crossed with 
mice expressing activated rat c-neu oncogene (Val664-Glu) under the control of the mouse 
mammary tumor virus promoter (MMTV-neu), which directs expression of neu oncogene 
to mammary epithelial cells (Muller, Sinn et al. 1988) (Jackson Laboratories, Strain 
#005038). COX-2flox/flox mice positive for MMTV-neu are denoted WTneu. Further, C57/BL6 
mice expressing Cre recombinase under the control of the LysM promoter, which directs 
expression of Cre to cells of myeloid lineage (Clausen, Burkhardt et al. 1999), were 
backcrossed on to the FVB/N background through 7 generations, utilizing the JAX Speed 
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Congenics Service (Jackson Laboratories) to ensure >99.9% FVB/N. LysM-Cre mice, which 
express the unfloxed wild type COX-2 gene, were retained as a second set of control mice 
and are denoted LysM-WT and LysM-WTneu. Crossing COX-2flox/flox (WT) mice with LysM-
Cre (LysM-WT) mice results in specific deletion of COX-2 in subsets of myeloid-derived 
cells, with the primary effect in macrophages and monocytes (Hui, Ricciotti et al. 2010), 
and are denoted COX-2MØKO or COX-2MØKOneu, as appropriate. For all experiments, LysM-
Cre and MMTV-neu were maintained heterozygous and genotypes verified by PCR of 
lysed tail DNA (Hui, Ricciotti et al. 2010, Markosyan, Chen et al. 2011). 
2.2.2 Cell Lines and Culture 
 NAF and SMF, two cell lines derived from mammary carcinomas harvested from 
MMTV-neu transgenic mice (Elson and Leder 1995), were kindly provided by Dr. Lewis 
Chodosh (University of Pennsylvania). SMF cells were cultured in high-glucose DMEM 
(Invitrogen) with 10% calf serum, 0.5% L-glutamine, 1% Pen/Strep, and 4 µg/mL insulin 
(”SMF medium”).  NAF cells were maintained in high-glucose DMEM with 10% fetal 
bovine serum, 0.5% L-glutamine, and 1% Pen/Strep (“10% FBS/DMEM”). Cells were split 
by incubating in 0.25% trypsin for 10 minutes. To make conditioned medium, SMF (6 x 107 
cells in a T175 flask in 20 mL SMF medium) were grown for 24 hours, washed twice with 
serum-free SMF medium and then incubated in fresh serum-free SMF medium for 24 
hours. The resultant conditioned medium (SMF-CM) was filtered and aliquoted for use in 
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migration experiments (see below).  
 To generate stable transfects expressing luciferase, luciferase-pcDNA3 (Addgene; 
Plasmid #26612) plasmid was inserted into pLKO.1-puro lentiviral plasmid vector and 
packaged into MISSION TRC Lentiviral Particles (Sigma-Aldrich, #CSTVRS). NAF cells were 
transduced using MISSION TRC Lentiviral Particles, according to manufacturer’s 
instructions. In brief, cells were treated with 8 µg/mL protamine sulfate (Sigma-Aldrich, 
#P4020) before transduction with 4.6 x 105 TU of luciferase lentiviral particles for 18 
hours. Selection was carried out under 2 µg/mL puromycin (Sigma-Adrich, P7130) for at 
least 2 passages. The resultant cells were termed NAFLuc and luciferase expression was 
confirmed by treatment with 150 μg/mL D-Luciferin (Sigma-Aldrich, #L6882) with 
subsequent fluorescence detection at 550 nm (VICTOR3 1420 Counter, Perkin Elmer). 
 L929 cells (American Type Culture Collection, #CCL-1) were maintained in 10% 
FBS/DMEM as a biological source of CSF-1 for bone marrow-derived macrophage (BMDM) 
culture (Davies and Gordon 2005). L929 cells cultured to 100% confluency in a T75 flask 
were split 1:5 and cell supernatants collected and stored after another 4 days of culture.  
2.2.3 Bone Marrow-Derived Macrophage Isolation, Culture, and Treatments 
 BMDM were isolated and cultured as described (Davies and Gordon 2005, Zhang, 
Goncalves et al. 2008). Briefly, bone marrow cells were flushed from female mouse 
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femurs with 10 mL cold DMEM from a 10 mL syringe through a 27 g needle. Cells were 
pelleted and plated in non-adherent tissue culture plates (Fisher Scientific, #08-757-14G) 
in L929 supernatants diluted 1:5 in 10% FBS/DMEM (L-cell conditioned medium, LCCM). 
After approximately 1 week of culture, bone marrow cells were washed two times with 
warm 10 mL DPBS then lifted by incubating in ice cold 10 mL DPBS for 20 minutes in a 4°C 
cold room. Pelleted cells were split into non-adherent tissue culture plates in LCCM and 
were ready to use following an additional week of culture. Cultured BMDM were serum-
starved for 24 hours before stimulation with 5 μg/mL lipopolysaccharide (LPS; Sigma-
Adrich, #L2630), M2 polarization cocktail (20 ng/mL IL-4 and 10 ng/mL IL-13, Peprotech, 
#210-13 and #214-14), or water as control. After 6 hours (for LPS-stimulated BMDM) or 
18 hours (for M2-polarized BMDM) at 37°C, supernatants were collected for eicosanoid 
measurement by mass spectrometry (described below) and cells were lysed for mRNA 
extraction (RNeasy Mini Kit, Qiagen, #74106) for gene expression analysis by Q-PCR 
(described below), or for protein extraction (radio-immunoprecipitation assay [RIPA] 
buffer with protease inhibitor; Complete Cocktail Tablet; Roche, 11697498) for COX-1 and 
COX-2 protein quantification by LC-MRM-MS (described below). For cell number assays, 
BMDM were seeded at 2 x 106 cells/plate in 10 cm2 plates and allowed to grow for 3 days, 
after which BMDM are lifted, as above, and counted. 
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2.2.4 Animal Experiments 
 COX-2MØKOneu and WTneu mice spontaneously develop tumors after 12 weeks of 
age, with 100% of mice tumor bearing by 32 weeks of age (Muller, Sinn et al. 1988). For 
orthotopic injection of tumor cells, SMF or NAFLuc tumor cells were treated with 0.25% 
trypsin for 10 minutes. SMF or NAFLuc cells were resuspended at 1 x 107 cells/mL and 
injected into the left and right #4 mammary glands of COX-2MØKO and WT mice between 
8-14 weeks of age (100 µL/gland; 1 x 106 cells). 
 For T cell depletion experiments, mice were intraperitoneally injected with 200 µg 
isotype control (Clone: C1.18.4, #BE0085), anti-CD4 (Clone GK1.5, #BE003-1), or anti-CD8 
(Clone 2.43, #BE0061) antibodies (BioXCell) 4 days prior to orthotopic injection of SMF 
cells. Mice in the CD8 depletion group received a second 200 µg dose of anti-CD8 antibody 
2 days prior to tumor cell injection. After orthotopic injection of SMF tumors cells, mice 
continued to receive isotype control or anti-CD4 antibody treatment once weekly, or anti-
CD8 antibody twice weekly, until the study’s conclusion. Depletion of CD4 or CD8 T cells 
was confirmed by flow cytometry of erythrocyte-lysed whole blood (ACK Lysing Buffer, 
Invitrogen, #A10492-01). 
 Mice with transgenic MMTV-neu expression or orthotopic injection of tumor cells 
were palpated twice weekly and considered tumor bearing if a palpable mass persisted 
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for at least 1 week. Palpable masses were measured with calipers, with tumor volume 
expressed as (length x width2)/2. At necropsy, tumors were counted and resected, then 
flash frozen in liquid nitrogen for mRNA isolation, stored in 10 mL Prefer (Anatech, #410) 
overnight and paraffin embedded by CHOP Pathology Laboratories, or digested for 2 
hours at 37°C in 5 mL complete EpiCult-B medium (Stemcell Technologies, #05610) 
containing 5% FBS and 10% collagenase/hyalurdoninase (StemCell Technologies, #07912) 
while shaking at 300 RPM. RNA was isolated from flash frozen tissue using RNEasy Mini 
tubes (Qiagen, #74106) after TissueLyser bead-based homogenization. Digested tissue 
was collected and treated with 5 mL 1:4 Hank’s Balanced Salt Solution (HBSS, Invitrogen, 
#14025076)/2% FBS: ammonium chloride solution (StemCell Technologies, #07800). After 
one wash, the pellet was treated with 5 mL 0.25% trypsin, washed with 10 mL 2% FBS in 
HBSS, pelleted, treated with 2 mL dispase and 200 μL DNase solution, filtered, and washed 
with 10 mL 2% FBS in HBSS before being resuspended in PBS for flow cytometric analysis.  
 Mice with orthotopic injection of NAFLuc cells were injected with 150 mg/kg D-
Luciferin (Gold Biotechnology, #LUCK-100) dissolved in DPBS, and scanned 15 minutes 
post injection in an IVIS Lumina II (Perkin Elmer) for detection of bioluminescence. Mice 
were scanned every 3 minutes for 21 minutes with data from scans with highest 
sensitivity (peak counts) used for sequence analysis and normalization. 
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2.2.5 Flow Cytometry 
 Single cell suspensions (BMDM, digested tumors, or erythrocyte-lysed whole 
blood) were washed in PBS and plated in 96 well plates at 1 x 106 cells/well. Cells were 
stained for viability using LIVE/DEAD Fixable Aqua (Life Technologies, #L34957,), then 
washed twice with PBS. Cells were treated with Fc Block (anti-mouse CD16/CD32, BD 
Pharmagen, #553142) before cell surface stain. Cell surface antibodies are listed as 
“extracellular” stains in Table 2-1. Stained cells were washed and fixed with Cytofix or 
Cytofix/Cytoperm (BD Pharmagen, #554655 and #554714) for intracellular staining. 
Permeabilized cells were stained with intracellular antibodies for cytokines or enzymes. 
Intracellular antibodies are list in Table 2-1. Flow cytometry was performed using a 4 laser 
LSR II (BD Biosciences). Compensation was performed using OneComp eBeads 
(eBioscience, #01-1111-41) stained with antibodies of the appropriate fluorophore.  
2.2.5 Quantitative-PCR 
RNA isolated from BMDM or whole tumors isolated above were quantified 
(NanoDrop Spectrophotometer) and reverse transcribed into cDNA (MultiScribe Reverse 
Transcriptase, Life Technologies, #4311235) according to manufacturer’s instructions. 
Quantitative real-time polymerase chain reaction (Q-PCR) was carried out using 
inventoried primer/probe gene expression assays with TaqMan Universal PCR Master Mix  
(Life Technologies, #4304437) for all genes with the exception of CSF-1R, where the 
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ANTIBODY LIST 
Antibody Fluorophore Intra/Extracellular Supplier Catalog 
CD3 FITC Extracellular BD Pharmingen 555274 
CD4 PE Extracellular Invitrogen MCD0404 
CD8a Alexa Fluor 647 Extracellular Invitrogen MCD0821 
F4/80 PE-Cy7 Extracellular eBioscience 25-4801-82 
Gr-1 APC-Cy7 Extracellular BD Pharmingen 557661 
CD11b PerCP-Cy5.5 Extracellular eBioscience 45-0112-80 
CSF-1R Alexa Fluor 488 Extracellular eBioscience 53-1152 
CD86 FITC Extracellular eBioscience 11-0862-81 
CD206 Alexa Fluor 647 Intracellular AbD serotec MCA2235A647T 
IFNγ Alexa Fluor 647 Intracellular BD Pharmingen 557735 
IL-4 PE-Cy7 Intracellular eBioscience 25-7042-41 
iNOS Alexa Fluor 647 Intracellular Santa Cruz sc-7271 AF647 
Arginase-1 FITC Intracellular R&D Systems IC5868F 
Table 2-1 List of antibodies used in flow cytometry experiments. 
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QuantiFast Probe Assay with 2 Step RT-PCR Master Mix with ROX dye (Qiagen, #204554) 
was used. Q-PCR products were monitored using the ViiaTM 7 Real-Time PCR System 
(Applied Biosystems) and data was analyzed using the 2-ΔΔCt method of relative 
quantification (RQ) (Bookout and Mangelsdorf 2003) using 18S for normalization and 
mixed M1/M2 polarized macrophage RNA (for BMDM) or WT tumor tissue (for tumors) 
as a calibrator.  
2.2.6 Mass Spectrometry 
Quantitation of eicosanoids and their associated metabolites was performed using 
ultra high pressure liquid chromatography/tandem mass spectrometry (UPLC/MS/MS) 
with negative electrospray ionization and multiple reaction monitoring (MRM), as 
described (Song, Lawson et al. 2007). Cell culture medium samples were spiked with 
tetradeuterated (d4) analogues (5ng) of PGD2, PGE2, 6-keto-PGF1α (PGI2 hydrolysis 
product), and TxB2 (TxA2 hydrolysis product) as internal standards for quantitation 
(Cayman Chemicals). Spiked cell culture medium was derivatized (1 g/mL methoxyamine 
HCl in water) and extracted using StrataX Solid Phase Extraction cartridges (Phenomenex). 
Extracts were dissolved in 20% acetonitrile/80% water before UPLC/MS/MS on a 
Quantum Ultra interfaced with an Accela UPLC system (Thermo Scientific, West Palm 
Beach, FL). The mobile phase was generated from Millipore water (mobile phase A) and 
5% methanol/95% acetonitrile (mobile phase B), both containing 0.005% acetic acid 
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adjusted to pH 5.7 with ammonium hydroxide. The flow rate was 350 μl/min.  An Acquity 
CSH C18 column (2.1 mm x 150 mm, 1.7 µm) was used with a segmented linear gradient 
starting at 20% B, ramping to 350% B (15’), then to 40% B (18’). The transitions monitored 
were as described (Song, Lawson et al. 2007). The collision gas was argon, 1.5 mTorr. The 
collision energy was 18 V. Source offset was 6 V. Quantitation was by peak area ratios. 
Quantification of cyclooxygenase peptide was performed by stable-isotope 
dilution liquid chromatography/mass spectrometry in multiple reaction monitoring mode 
(LC-MRM-MS) (Ciccimaro and Blair 2010). Whole macrophage protein lysates were 
separated by SDS-PAGE. After staining with Coomassie Brilliant Blue G-250, gel bands with 
molecular weight corresponding to the COX-1 electrophoresis standard (Cayman) were 
excised. Following destaining, reduction, and alkylation (Li, Xie et al. 2009), heavy amino 
acid labeled internal standards for two unique proteolytic peptides from mouse COX-1 
(FGLKPYTSFQELTGEK and VPDYPGDDGSVLVR) and COX-2 (NVPIAVQAVAK and 
LDDINPTVLIK) were spiked before overnight trypsin digestion. Liquid chromatography and 
multiple reaction monitoring mass spectrometry (LC-MRM) analysis was performed on a 
TSQ Vantage triple stage quadrupole mass spectrometer (Thermo Scientific) interfaced 
with a Nano-ACQUITY UPLC system (Waters) as described (Wehr, Hwang et al. 2012). 
Twenty-four transitions were monitored with three unique transitions for each peptide. 
Quantification information was extracted from the peak areas of the transitions using 
45 
 
  
Xcalibur Quan Browser (Thermo Scientific). Absolute COX-1 and COX-2 protein 
expressions were calculated using the ratio of peak area of the endogenous peptides to 
corresponding internal standard.  
2.2.7 Immunohistochemistry 
For anti-CD3 (Abcam, #ab5690; 1:100) stained sections, mammary tumor sections 
were deparaffinized in Citrosolv (Fisher, #670209) and rehydrated through a descending 
series of ethanol washes. Antigen retrieval was performed in 1 mM EDTA in a 100°C water 
bath for 20 min. After cooling, endogenous peroxidase was blocked with 3% hydrogen 
peroxide, followed by 1 hr blocking in 10% normal donkey serum. Primary antibody 
treatments were for 1 hr at room temperature followed by visualization using the Rabbit 
Polink-2 HRP Plus AEC System (Golden Bridge International, #D16-18) according the 
manufacturer’s instructions.  
 For anti-cleaved caspase-3 (R&D System, #MAB835; 1:100), anti-Ki67 (Abcam, 
#ab16667; 1:400), and anti-Von Willebrand Factor (Dako, #A0082; 1:750) stained 
sections, tissue sections were deparraffinized in xylene and similarly rehydrated through 
descending concentrations of ethanol.  Peroxidase blocking was performed using 3% 
hydrogen peroxide in methanol for 30 min. Slides were pretreated in a pressure cooker 
(Biocare Medical) in Antigen Unmasking solution (Vector Labs, #H-3300).  After cooling, 
slides were rinsed in 0.1 M Tris Buffer then blocked with 2% FBS for 15min.  Slides were 
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also blocked for endogenous biotin using the avidin biotin blocking kit (Vector Lab, #SP-
2001) followed by Protein Block (Dako, #X0909) for 10 min then incubated for 1hr at room 
temperature in primary antibody.  Slides were again rinsed then incubated with 
biotinylated anti-rabbit IgG (Vector Lab, #BA-1000) for 30 min, washed, then incubated 
with the avidin biotin complex (Vector Lab, #PK-4000) for 30 min, washed, and finally 
incubated with diaminobenzidine (Dako, #K3467) for 10 min.  Slides were then rinsed and 
counterstained with hematoxylin (Fisher Scientific, #751755) for approximately 30 
seconds, then rinsed, dehydrated through a series of ascending concentrations of ethanol 
and xylene, then cover-slipped. 
 Microscopy was performed using an Olympus AX70 upright compound 
microscope, with images acquired with an Olympus DP72 12.8 megapixel digital color 
camera using cellSens Entry 1.5.  
2.2.8 Migration Assay 
BMDM migration was assessed through a modified Boyden Chamber assay 
(Green, Liu et al. 2009, Park, Febbraio et al. 2009, Low-Marchelli, Ardi et al. 2013). BMDMs 
were cultured and lifted, as above, plated at 4 x 104 cells/300 µL on 8.0 µm pore Transwell 
Permeable Supports (Corning, #3422) in LCCM, and overlaid on 800 µL LCCM in a 24 well 
plate. BMDM were allowed to adhere overnight, then inserts were washed, laid over 
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serum-free medium, and BMDM serum starved for 6 hours. After 6 hours, the bottom 
well was replaced with medium containing serum-free medium, 20 - 80 ng/mL CSF-1 
(Peprotech, #315-02), 50% - 75% SMF-conditioned medium (see above), or 75% SMF-
conditioned medium with CSF-1 neutralization antibody (BD Pharmingen, #552513). Cells 
were allowed to migrate for 18 hrs before inserts were scraped on their upper layer and 
then dropped into 0.1% crystal violet in 2% ethanol for 15 min. Inserts were washed three 
times with DPBS, and crystal violet eluted using 10% acetic acid. Eluate was transferred 
to a 96 well plate for absorbance measurement at 562 nm. 
2.2.9 Statistical Analysis 
 All significance testing was performed with non-parametric two-sample Mann-
Whitney tests or Log-rank (Mantel-Cox) tests for survival analysis.  Paired tests were 
performed when appropriate. Statistical analyses were performed using Prism (GraphPad 
Software). Handling of multiple testing was done through estimation of the number of 
false positives. A total of 130 two-sample tests were performed, with a significance 
threshold of 0.05. A total of 52 of the 130 p-values are significant at the 0.05 level.  We 
therefore would expect 0.05 * 130 = 6.5 false positives from 130 tests if all null hypotheses 
were true.  Thus we (conservatively) expect approximately 45 of our rejected null 
hypotheses to be correctly rejected.  With 45 true positives, the expected number of 
falsely rejected null hypotheses falls to 0.05 * 85 = 4.25.  Therefore we can 
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(conservatively) expect five false positives from the 52 rejected null hypotheses.  This 
number is still conservative since many of the observed p-values are very small.  The 
overall conclusions of this Chapter are robust to a small number of false positives, 
particularly among the hypotheses with marginal p-values. 
2.3 Results 
2.3.1 Specific Deletion of Macrophage COX-2 
COX-2MØKO mice homozygous for LysM-Cre (COX-2flox/floxLysM-Cre+/+) were 
previously characterized by the FitzGerald Lab on a C57BL/6 background (Hui, Ricciotti et 
al. 2010). Because of the knock-in strategy used, LysM-Cre+/+ mice are null for endogenous 
LysM (Clausen, Burkhardt et al. 1999) raising a concern that lysozyme M ablation in our 
model might confound the effects of COX-2 depletion. To allay this concern, COX-2MØKO 
mice were maintained as heterozygous for LysM-Cre (COX-2flox/floxLysM-Cre+/-), thereby 
retaining one native LysM allele. We first reconfirmed successful COX-2 deletion with 
LysM-Cre heterozygousity on the FVB/N background. LPS-treated BMDMs isolated from 
COX-2MØKO mice had a greater than 90% reduction in COX-2 mRNA by Q-PCR (Figure 2-
2A) and with no changes in either COX-1 mRNA or COX-1 peptide as compared to WT 
(Figure 2-2B). LPS-treated COX-2MØKO BMDMs also had over 50% reduced COX-2 peptide 
by LC-MRM-MS (Figure 2-2A), which ablated both basal and LPS-induced generation of 
PGE2 (Figure 2-2C). In addition, basal and LPS-induced PGD2, but not TxA2, generation was 
49 
 
  
reduced and, though a minor product, LPS-induced PGI2 generation was significantly 
lower in COX-2MØKO BMDM (Figure 2-2C). To confirm specific deletion of COX-2 in 
macrophages, tissues of organs that constitutively express COX-2 were extracted and 
analyzed for COX-2 mRNA by Q-PCR. COX-2 mRNA levels were unchanged in COX-2MØKO 
mice brain and kidney (Figure 2-2D). 
2.3.2 Reduced Mammary Tumorigenesis in COX-2MØKO Neu-Driven Spontaneous Tumors 
 For both WTneu and LysM-WTneu mice, which are transgenic for an activated rat c-
neu oncogene (Val664 to Glu664 mutation) under control of MMTV and express native COX-
2, median tumor free survival was 22 weeks. Tumor onset was significantly delayed in 
COX-2MØKOneu mice, which had a median tumor free survival of 25 weeks (Figure 2-3A). 
Tumor multiplicity, at the time of sacrifice, was reduced by >30% (Figure 2-3B) in COX-
2MØKOneu mice as compared to either WTneu or LysM-WTneu. This was accompanied by 
reduced tumor growth in COX-2MØKOneu mice, as measured by size of largest tumor per 
animal (Figure 2-3C) or by the number of weeks that elapsed before the largest tumor in 
each animal reached a volume of 0.25cm3 (Figure 2-3D). Thus, deletion of macrophage 
COX-2 significantly reduced disease burden defined by tumor onset, multiplicity, and 
growth. WTneu and LysM-WTneu did not significantly differ from each other in any of the 
endpoints, indicating that reduced disease in COX-2MØKOneu was not due to deletion of 
one LysM allele. Having confirmed an equivalent gross tumorigenic phenotype in WTneu 
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Figure 2-2 Selective deletion of macrophage COX-2 in COX-2MØKO mice.  
BMDM were stimulated with LPS (5μg/mL, 6 hrs) to induce COX-2 expression. COX-2 (A) mRNA (Left, n=6) and peptide 
(Right, n=5-7) was significantly reduced in COX-2MØKO BMDM as compared to WT BMDM while (B) COX-1 mRNA and 
peptide were maintained. (C) LPS-induced PGE2 and PGD2 synthesis in COX-2MØKO BMDM was abolished and markedly 
decreased (respectively) compared to WT (n=4). (D) Constitutive expression of COX-2 was not altered in kidney or brain 
of COX-2MØKO mice compared to WT mice (n=4). RQ = relative quantity. Data are mean ± SEM. *p<0.05, **p<0.01, 
***p<0.001, n.s. = not significant. 
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Figure 2-3 Deletion of macrophage COX-2 reduces tumorigenesis in neu oncogene-driven spontaneous tumors.  
(A) Tumor onset was delayed (n=20), (B) tumor multiplicity decreased (n=19-20), and (C) tumors were smaller (n=13-
17) in COX-2MØKO mice transgenic for MMTV-neu (COX-2MØKOneu) as compared to control WTneu or LysM-WTneu mice. 
(D) COX-2MØKOneu tumors were slower to reach a volume of 0.25cm3 as compared to control mice (n=18-19). Data are 
mean ± SEM. *p<0.05, **p<0.01, ***p<0.001. In (C), aComparison between WTneu and COX-2MØKOneu, bComparison 
between LysM-WTneu and COX-2MØKOneu. 
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and LysM-WTneu mice, further studies use WTneu as the control COX-2 sufficient group. 
 To explore the complex biology underlying reduced disease in COX-2MØKOneu mice, 
we examined indices of proliferation, apoptosis, angiogenesis, and immune cell 
composition. No significant differences were observed in tumor mRNA levels or 
immunohistochemical staining of activated caspase-3, a marker of apoptosis (Figure 2-
4A, 2-5) in COX-2MØKOneu as compared to WTneu. Similarly, expression of Ki67, a marker of 
cell proliferation, was unchanged between the two genotypes (Figure 2-4A, 2-6). With 
respect to tumor angiogenesis, expression of VEGFA mRNA was decreased in COX-
2MØKOneu while expression of its receptor, VEGFR2, increased (Figure 2-4B). However, 
other markers of angiogenesis were not significantly different, and immunohistochemical 
staining of tumor sections for Von Willebrand Factor, to identify vascular endothelium 
(Figure 2-7), also revealed no changes between genotypes. Thus, we concluded that 
tumor angiogenesis was not significantly altered by macrophage COX-2 deletion, at least 
when examined in well-established tumors. Finally, we investigated differences in the 
number of tumor infiltrating immune cells and found no significant changes in total TAMs 
(F4/80+CD11b+Gr-1-), MDSCs (Gr-1+CD11b+), NK cells (CD3-CD8+), neutrophils (Gr-
1+F4/80), or T cells (CD3+) by flow cytometry (DeNardo, Barreto et al. 2009) in COX-
2MØKOneu mice as compared to WTneu mice (Figure 2-8). Together, these studies did not 
reveal a mechanistic explanation for reduced tumorigenesis in COX-2MØKOneu mice. 
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Figure 2-4 Analysis of apoptosis, proliferation, and angiogenesis in spontaneous tumors by Q-PCR.  
No difference was observed in mRNA levels of (A) caspase-3 or Ki67 (n=4-7) in COX-2MØKOneu tumors. (B) Expression 
of markers of angiogenesis (n=4-7) were not consistently altered in COX-2MØKOneu tumors. Data are mean ± SEM. 
*p<0.05, n.s. = not significant. VEGF = vascular endothelial growth factor, R = receptor. 
Figure 2-5 Immunostaining of activated-caspase 3 in spontaneous tumors.  
No major differences were observed by immunostaining of activated-caspase 3, as a marker of apoptosis, in COX-
2MØKOneu versus WTneu tumors. Images are two representative slides shown at 20X magnification at room temperature. 
Scale bars are 200μm. Arrows show positive staining. 
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Figure 2-7 Immunostaining of Von Willebrand Factor in spontaneous tumors.  
No major differences were observed by immunostaining of Von Willebrand Factor (Factor VIII), as a marker of vascular 
endothelium, in COX-2MØKOneu versus WTneu. Images are two representative slides shown at 20X magnification at room 
temperature. Scale bars are 200μm. Arrows show positive staining. 
Figure 2-6 Immunostaining of Ki67 in spontaneous tumors.  
No major differences were observed by immunostaining of Ki67, as a marker of proliferation, COX-2MØKOneu versus 
WTneu. Images are two representative slides shown at 20X magnification at room temperature. Scale bars are 200μm. 
55 
 
  
   
Figure 2-8 Immune composition of spontaneous tumors.  
Flow cytometry of enzymatically digested spontaneous tumors indicated no change in density of tumor associated 
macrophages (TAM, F4/80+/CD11b+/Gr-1-), natural killer (NK) cells (CD3-CD8+), neutrophils (Gr-1+F4/80-), myeloid-
derived suppressor cells (MDSC; Gr-1+CD11b+) or T cell (CD3+) between COX-2MØKOneu and WTneu tumors (n=4-11). 
RQ = relative quantity. Data are mean ± SEM. n.s. = not significant. 
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However, analysis of spontaneous tumors was challenging for a number of reasons – first, 
given the more aggressive disease in WTneu mice, compared to COX-2MØKOneu, euthanasia 
of the former group was routinely performed several weeks prior to the latter, limiting 
side-by-side comparison of similar age and stage tumors. Further, at the time of tumor 
harvest (approximately two weeks after palpation), tumors were quite large, late stage 
tumors, at which point we suspect disease-modifying changes in tumor characteristics 
and microenvironment may be blunted. Therefore, to study further the mechanism 
behind reduced tumorigenesis in COX-2MØKO mice, we developed a syngeneic orthotopic 
model of MMTV-neu-driven mammary tumorigenesis. 
2.3.3 Reduced Mammary Tumorigenesis in COX-2MØKO Neu-Driven Orthotopic Tumors 
 Orthotopic injection of SMF and luciferase-expressing NAF (NAFLuc), both 
mammary tumor cell lines derived from MMTV-neu transgenic mice (Elson and Leder 
1995), generate palpable tumors within one week of injection. SMF and NAFLuc cells were 
injected into mammary fat pads of syngeneic immune competent WT or COX-2MØKO host 
mice (these mice were not transgenic for MMTV-neu oncogene).  As in the spontaneous 
model, tumor growth was substantially depressed in host COX-2MØKO mice receiving SMF 
(caliper measurements, Figure 2-9A) or NAFLuc (IVIS optical imaging, Figure 2-9B) as 
compared to WT hosts. As above, tumor growth was not different between WT and LysM-
WT hosts confirming that deletion of one LysM allele in COX-2MØKO mice was not 
57 
 
  
 
 
  
Figure 2-9 Deletion of macrophage COX-2 reduces tumorigenesis, COX-2 expression, and mPGES-1 expression in neu 
oncogene-driven orthotopic tumors.  
(A) SMF mammary tumor cells grew more slowly in COX-2MØKO hosts as compared to WT and LysM-WT hosts (n=17-
20). (B) NAF mammary tumor cells stably expressing luciferase grew more slowly and were less likely to seed and sustain 
tumor growth in COX-2MØKO hosts as compared to WT hosts. (C) COX-2 and mPGES-1 mRNA levels were reduced in 
COX-2MØKO tumors as compared to WT tumors (n=4-6). Data are mean ± SEM. RQ = relative quantity. aComparison 
between WT and COX-2MØKO, bComparison between LysM-WT and COX-2MØKO. *p<0.05, **p<0.01, ***p<0.001, n.s. = 
not significant. 
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sufficient to explain the reduction in tumor growth (Figure 2-9A). In tumors isolated from 
COX-2MØKO host mice, COX-2 mRNA levels were markedly reduced, with coincident 
suppression of mPGES-1, the PGE2 synthesis enzyme that lies downstream of COX-2 
(Figure 2-9C,D). The coincident loss of COX-2 and mPGES-1 likely reflects loss of PGE2-
induced mPGES-1 expression (Obermajer, Muthuswamy et al. 2011, Diaz-Munoz, Osma-
Garcia et al. 2012). The extent to which COX-2 was suppressed COX-2MØKO tumors was 
perhaps surprising, given that the restricted nature of LysM-direct COX-2 excision. It may 
be that macrophages are a dominant source of COX-2 in these tumors. Alternatively, loss 
of macrophage COX-2 may interfere with paracrine induction of COX-2 expression by 
other cells, including tumor cells (Lai, Chen et al. 2010). Unfortunately, 
immunohistochemical staining of tumor sections did not provide sufficient resolution to 
confirm cell-specific COX-2 expression. Investigation of apoptosis and proliferation in 
orthotopic tumors gave similar results as the spontaneous model with no discernable 
differences between host genotypes in caspase-3 or Ki67 expression by mRNA 
quantification (Figure 2-10A) or through immunohistochemistry (Figure 2-11,12). Further, 
tumor vascularity was not consistently different between tumors from WT and COX-
2MØKO host genotypes by staining for Von Willebrand Factor (Figure 2-13) or 
quantification of mRNA for VEGFs and their receptors (Figure 2-10B). 
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2.3.4 Deletion of Macrophage COX-2 Reduces TAMs Density and Alters TAM Phenotype 
 A marked decrease in TAM density, defined as F4/80+CD11b+Gr-1- cells as a 
function of total live-gated immune cells (DeNardo, Barreto et al. 2009), was evident in 
orthotopic tumors grown in COX-2MØKO compared to WT hosts (Figure 2-14), while no 
changes were observed in the proportion of NK cells, neutrophils, or MDSCs by flow 
cytometry, gated as outlined in the previous section (Figure 2-14), between host 
genotypes. CSF-1 is an essential growth factor and chemokine in macrophages, which also 
drives a pro-tumorigenic macrophage/EGF-tumor cell/CSF-1 paracrine loop (Wyckoff, 
Wang et al. 2004, Hernandez, Smirnova et al. 2009). We investigated whether modulation 
of the CSF-1/CSF-1 receptor (R) system contributed to reduced TAMs in COX-2MØKO 
tumors. By flow cytometry, surface CSF-1R levels were not different between TAMs 
harvested from WT or COX-2MØKO (Figure 2-15A), suggesting that TAMs that have 
infiltrated tumors, even COX-2MØKO tumors, have sufficient expression on CSF-1R 
expression. We next examined BMDMs harvested from tumor-naïve COX-2MØKO and WT 
mice, as a model of macrophages that have not yet circulated or infiltrated a tumor, we 
found significantly reduced CSF-1R mRNA levels and cell surface CSF-1R expression 
(Figure 2-16B,C). Interestingly, M2 polarization of BMDM results in suppression of CSF-1R 
in WT BMDM, removing any difference between CSF-1R expression in WT and COX-2MØKO 
BMDM (Figure 2-16B), which suggests that transition to the M2-like phenotype of TAM 
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Figure 2-11 Immunostaining of activated-caspase 3 in orthotopic tumors.  
No major differences were observed by immunostaining of activated-caspase 3, as a marker of apoptosis, in SMF 
mammary tumor cell orthotopic tumors. Images are two representative slides shown at 20X magnification at room 
temperature. Scale bars are 200μm. Arrows show positive staining. 
Figure 2-10 Analysis of apoptosis, proliferation, and angiogenesis in orthotopic tumors by Q-PCR.  
No difference was observed in mRNA levels of (A) caspase-3 or Ki67 (n=12-13) in COX-2MØKO tumors. (B) Expression 
of markers of angiogenesis (n=5-6) were not consistently altered in COX-2MØKO tumors. Data are mean ± SEM. 
*p<0.05, n.s. = not significant. VEGF = vascular endothelial growth factor, R = receptor. 
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Figure 2-12 Immunostaining of Ki67 in orthotopic tumors.  
No major differences were observed by immunostaining of Ki67, as a marker of proliferation, in SMF mammary tumor 
cell orthotopic tumors. Images are two representative slides shown at 20X magnification at room temperature. Scale 
bars are 200μm. 
 
Figure 2-13 Immunostaining of Von Willebrand Factor in spontaneous tumors.  
No major differences were observed by immunostaining of Von Willebrand Factor (Factor VIII), as a marker of vascular 
endothelium, in SMF mammary tumor cell orthotopic tumors. Images are two representative slides shown at 20X 
magnification at room temperature. Scale bars are 200μm. 
62 
 
  
  
Figure 2-14 Deletion of macrophage COX-2 alters the tumor immune composition in orthotopic tumors.  
Flow cytometry of enzymatically digested tumors revealed a reduction In the proportion of tumor-associated 
macrophages, and an increase in the proportion of T cells in COX-2MØKO tumors, as compared to WT (n=4-11). No 
difference was observed in NK cells, neutrophils, or MDSCs. Data are mean ± SEM. **p<0.01, n.s. = not significant. 
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normalizes levels of WT and COX-2MØKO macrophage CSF-1R. We reasoned that reduced 
CSF-1R expression in macrophages may impair macrophage migration and/or 
proliferation, thus leading to lower TAMs in COX-2MØKO tumors. Similar growth of COX-
2MØKO and WT BMDMs in vitro (Figure 2-15D) argue against an impact on proliferation. 
However, compared, to WT BMDM, dose-dependent migration of COX-2MØKO BMDM 
towards recombinant CSF-1 was significantly reduced (Figure 2-16A), suggesting that 
lower TAM density in COX-2MØKO tumors may be due to reduced migration of 
macrophages in response to tumor cell-derived CSF-1. Consistent with this notion, 
migration of COX-2MØKO toward SMF conditioned-medium (SMF-CM) was also 
suppressed, as compared to WT BMDM. Pretreatment of SMF-CM with a CSF-1 
neutralizing antibody reduced migration of WT BMDM to COX-2MØKO BMDM levels 
(Figure 2-16B), confirming CSF-1 as a primary BMDM chemoattractant in SMF-CM.  
Depending on their phenotype, TAM may have anti- or pro-tumorigenic functions 
(Sica and Mantovani 2012). Importantly, M2-like TAM can suppress T cell survival and 
alter T cell function through arginine depletion and upregulation of T cell co-inhibitory 
molecules (Chen and Smyth 2011, Laoui, Movahedi et al. 2011). To examine whether COX-
2 deletion in macrophages modulates TAM phenotype, gene expression analysis was 
performed on a number of macrophage phenotypic markers. Analysis of whole tumors 
revealed reduced expression of M2 enzyme arginase-1, the M2 cytokine IL-10, and a 
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number of pro-inflammatory M1 markers, such as iNOS, CD86, and IL-6 in COX-2MØKO 
host tumors (Figure 2-17A), consistent with a reduction overall TAMs in COX-2MØKO 
tumors. Investigation of the TAM subpopulation, by flow cytometry, revealed that 
expression of M1 markers TNFα, iNOS, and CD86 was unchanged between COX-2MØKO 
and WT hosts, while intracellular expression of arginase-1 and cell surface expression of 
CD206 (mannose receptor) was significantly reduced (Figure 2-17B). Reduced M2 marker 
expression may suggest a lower immunosuppressive capacity by TAMs, a key component 
in TAM support of tumors. Interestingly, although TAM density was similar in 
spontaneous WTneu and COX-2MØKOneu tumors (see Figure 2-8 and above), loss of 
arginase-1 and CD206 was equally evident in TAM isolated from spontaneous and 
orthotopic COX-2MØKO compared to WT tumors (Figure 2-17C). Taken together, these 
data indicate that macrophage COX-2 contributes to an autocrine loop in which COX-2-
derived products support a pro-tumorigenic M2 phenotype within the mammary tumor 
microenvironment. COX-2 deletion may lead, therefore, to less immunosuppressive 
TAMs, in turn leading to reduced disease in COX-2MØKO mice. 
2.3.5 Deletion of Macrophage COX-2 Enhances T Cell Density and CTL Tumor Function 
 Flow cytometry of COX-2MØKO host tumors revealed a substantial increase in T cell 
density as a proportion of tumor immune cells (see Figure 2-14), which was also apparent 
in immunohistochemical staining of tumor sections (Figure 2-18). We considered whether 
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Figure 2-15 Deletion of macrophage COX-2 reduces CSF-1R expression on bone marrow-derived macrophages.  
While (A) COX-2MØKO TAM had similar expression of CSF-1R as compared to WT TAM (by flow cytometry, n=3-4), naïve 
COX-2MØKO BMDM had reduced cell surface expression of CSF-1R by (B) Q-PCR (n=6) and (C) flow cytometry (n=4). (B) 
M2 polarization (20ng/mL IL-4 and 10ng/mL IL-13, 18 hrs) reduced WT BMDM expression of CSF-1R but did not further 
alter COX-2MØKO BMDM expression.  (D) WT and COX-2MØKO BMDM had similar cell numbers when cultured in vitro 
after 3 days of culture (n=6). RQ = relative quantity. Data are mean ± SEM. *p<0.05, n.s. = not significant. 
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Figure 2-16 Deletion of macrophage COX-2 impairs macrophage migration.  
Migration of COX-2MØKO BMDM was significantly reduced as compared to WT BMDM towards (A) CSF-1 or (B) 
conditioned medium from SMF tumors cells (SMF-CM, n=5-10). (B) Addition of CSF-1 neutralizing antibody ablated WT 
BMDM migration towards SMF-CM (n=3). Data are mean ± SEM. **p<0.01, ***p<0.001, n.s. = not significant. 
Figure 2-17 Tumor-associated macrophages in COX-2MØKO mice display an altered macrophage phenotype.  
(A) Q-PCR for mRNA levels of several M1 (iNOS, CD86, IL-6) and M2 (arginase-1, and IL-10) markers were lower in tumor 
tissue isolated from COX-2MØKO hosts as compared to WT (n=4-6). (B) Flow cytometric analysis of live gated TAMs 
(F4/80+CD11b+Gr-1-) revealed a lower proportion of M2 (arginase-1 and mannose receptor, CD206, positive) TAMs with 
no change in M1 (CD86, iNOS, or TNFα positive) TAMs in COX-2MØKO orthotopic tumors compared to WT (n=3-6). (C) 
By flow cytometry, the proportion of arginase-1 and CD206 positive TAM was also reduced in spontaneous neu-driven 
tumors (n=5-6). Data are mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, n.s. = not significant. 
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Figure 2-18 Immunostaining of CD3 in orthotopic tumors reveals increased T cell infiltration.  
Increased immunostaining for CD3 is evident in COX-2MØKO orthotopic tumor sections compared to WT. Images are 
two representative slides shown at 20X magnification at room temperature. Scale bars are 200μm. Arrows indicate CD3 
positive cells. 
 
Figure 2-19 Enhanced CD3+ population reflects increase in both CD4+ and CD8+ T cells.  
(A) The proportion of both CD4+CD3+ T lymphocyte and CD8+CD3+ CTL subpopulations was increased in COX-2MØKO 
tumors as compared to WT tumors (n=7). (B) No significant difference was observed by Q-PCR for Tbet (Th1), Gata3 
(Th2), or FoxP3 (regulatory T cell) mRNA in COX-2MØKO orthotopic tumors compared to WT (n=4-6). (C) No difference 
was observed between genotypes in proportion of IL-4 or IFNγ expressing CD4+CD3+ (n=4). (D) The proportion of 
regulatory T cells in COX-2MØKO orthotopic tumors was not different to that of WT by flow cytometry (n=3). RQ = relative 
quantity. Data are mean ± SEM. **p<0.01, n.s. = not significant. 
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increased chemoattraction of T cells could explain the change in T cell density. However, 
CCL5 (RANTES), an important T cell chemoattractant produced by monocytes, was 
undetectable in tumors arguing against increased migration of T cells in COX-2MØKO host 
tumors. It is likely, therefore, that the reduction in M2-like TAM and total TAM, which 
release immunosuppressive cytokines, express T cell co-inhibitory molecules, and deplete 
arginine, in COX-2MØKO tumors was responsible for the enhanced T cell presence. 
 The data thus far suggests that reduced total and immunosuppressive TAMs may 
lead to enhanced T cell survival. We sought to determine if the increase in any particular 
T cell subset contributed to reduced tumorigenesis. Analysis of T cell subsets into CD4+ T 
cells, which include TH1, TH2, and TREGs, and CD8+ CTLs revealed increases in both 
subpopulations in COX-2MØKO hosts (Figure 2-19A). Further analysis of tumor tissue by Q-
PCR for a Tbet (TH1 marker), Gata3 (TH2 marker), and FOXP3 (TREG marker) suggested a 
shift towards the immunosuppressive TH2 and TREGs in COX-2MØKO hosts, although 
statistical significance was not reached (Figure 2-19B). However, flow cytometric 
examination of the CD3+CD4+ subpopulation revealed no change in expression of IFNγ (as 
a marker of TH1) or IL-4 (as a marker of TH2), and a trend towards increased FOXP3 
remained non-significant (Figure 2-19C,D). Thus, we concluded that the elevation in CD4+ 
T lymphocytes in COX-2MØKO host tumors did not reflect elevation in any individual CD4+ 
T cell subtype. We next utilized antibody-mediated depletion of CD4+ and CD8+ T cell 
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subsets to investigate the contribution of these subsets to the suppressed tumor 
phenotype in COX-2MØKO hosts. We first confirmed depletion of CD4+ and CD8+ T cells in 
whole blood after red blood cell lysis – treatment with CD4 antibody depleted CD3+CD4+ 
T cells in whole blood, while treatment with CD8 antibody depleted CD3+CD8+ T cells in 
both WT and COX-2MØKO animals (Figure 2-20A). Growth of orthotopically injected SMF 
tumor cells in WT and COX-2MØKO hosts treated with CD4 antibody closely mirrored 
growth of mice treated with isotype control antibody (Figure 2-20B), suggesting that CD4+ 
T cells do not play a major role in reduced tumorigeneiss in COX-2MØKO mice. In marked 
contrast, depletion of CD8+ T cells restored growth of SMF orthotopic tumors in COX-
2MØKO mice such that their growth closely resembled isotype control treated WT hosts 
(Figure 2-20C), suggesting that CD8+ T cells are an essential T cell subset determining 
reduced tumorigenesis in COX-2MØKO mice. Further, loss of CD8+ T cells in WT mice 
enhanced tumor growth in these mice as compared to isotype control-treated WT mice, 
strongly implicated CD8+ T cells as an anti-tumorigenic effector cell in this model. 
Consistent with these data, an inverse relationship between CD8+ T cells and TAM was 
evident in spontaneous WTneu (but not COX-2MØKOneu) tumors (Figure 2-21), suggesting 
that, similar to the orthotopic model, loss of TAM-mediated CTL suppression in the 
spontaneous model contributed to reduced tumorigenesis and growth. 
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Figure 2-20 Antibody depletion of CD8+ cells restores orthotopic tumor growth in COX-2MØKO mice. 
 (A) Depletion of CD4+ (Left) and CD8+ (Right) T cells in mice treated with an anti (α)-CD4 or α-CD8 antibody was 
confirmed by flow cytometry of red blood cell-lysed whole blood (n=3). (B) Depletion of CD4+ T cells did not significantly 
alter tumor growth in COX-2MØKO or WT mice (n=6). (C) Depletion of CD8+ T cells increased tumor growth in WT mice 
and restored tumor growth in COX-2MØKO to WT levels (n=6). Data are mean ± SEM. aComparison between COX-2MØKO 
isotype vs COX-2MØKO α-CD8, bComparison between WT isotype vs COX-2MØKO α-CD8, *p<0.05, **p<0.01, n.s. = not 
significant. 
 
 
Figure 2-21 Increased TAMs correlate with fewer CTLs in WT, but not COX-2MØKO spontaneous tumors. 
(A) Total TAM and CD3+CD8+ CTLs, as a percentage of tumor immune cells, were inversely correlated in spontaneous 
WTneu tumors (Left, n=10) but not in spontaneous COX-2MØKOneu tumors (Right, n=9). 
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2.4 Discussion 
Deletion of COX-2 specifically from macrophages led to reduced tumorigenesis in 
two models of HER2/neu-induced mammary tumorigenesis. Reduced tumorigenesis was 
evident by delayed tumor onset, reduced tumor multiplicity, and suppressed tumor 
growth in spontaneous MMTV-neu-driven mammary tumors. The challenges of a side-by-
side comparison of spontaneous tumors from WTneu and COX-2MØKOneu limited 
mechanistic insight. In addition, because tumor growth was a primary endpoint in this 
study, spontaneous tumors were allowed to progress for several weeks after tumor onset, 
at which point harvested tumors were typically large, aggressive, and highly vascularized. 
We turned, therefore to an orthotopic model of mammary tumorigenesis to determine 
how deletion of macrophage COX-2 affects tumor progression. After first establishing a 
similar pattern of delayed tumor growth in COX-2MØKO mice, we observed reduced TAM 
density, likely due to lower levels of CSF-1R, the receptor for the essential macrophage 
growth factor and chemokine CSF-1, on COX-2MØKO macrophages limiting their migration 
to the tumor site. Further, a reduced pro-tumorigenic M2 phenotype was evident in TAM 
in COX-2MØKO tumors and this was consistent across both spontaneous and orthotopic 
models. We also observed a higher T cell population in COX-2MØKO host mice as compared 
WT hosts, which was not reflective of any particular T cell subset and seemed 
independent of T cell chemoattraction events involving COX-2MØKO macrophages. We 
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thus suspected that enhanced T cell survival may be due to the reduction in total and M2-
like TAMs leading to reduced immunosuppressive TAM function. Concordantly, depletion 
of CD8+ cells restored tumor growth in these animals to levels similar to that of isotype 
control-treated WT mice, indicating that enhanced CD8+ T cells was a primary effector cell 
in reduced tumorigenesis in COX-2MØKO host mice. 
 These studies highlight of the vital role of stromal COX-2 in directing 
tumorigenesis. Global COX-2 inhibition has been shown to reduce breast cancer risk 
(Harris 2009) and reduce mammary tumorigenesis in multiple rodent models of breast 
cancer (Lanza-Jacoby, Miller et al. 2003), though enthusiasm for COX-2 inhibitors has 
been dampened due to the cardiovascular side effects associated with their use (Grosser, 
Fries et al. 2006, Grosser, Yu et al. 2010). Systemic COX-2 inhibition leads to loss of 
vascular COX-2-derived prostacyclin, an antithrombotic agent, with unrestrained 
generation of COX-1-derived thromboxane, which promotes coagulation, leading to 
increased risk of thrombosis. Successful identification of a therapy in which macrophage 
COX-2 is specifically inhibited may provide a chemopreventative or chemotherapeutic 
agent that maintains (or has enhanced) efficacy of COX-2 inhibitors while reducing 
adverse events profile associated with systemic COX-2 inhibition. The 
immunosuppressive effects of paracrine and autocrine PGE2 in macrophages are well 
documented (Chen and Smyth 2011, Greene, Huang et al. 2011), and PGE2 is considered 
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the dominant pro-tumorigenic COX-2-derived prostanoid (Greenhough, Smartt et al. 
2009). We thus suspect loss of macrophage COX-2-derived PGE2 as a primary mediator in 
reduced immunosuppressive macrophage phenotype and overall tumorigenesis in COX-
2MØKO mice. However, at least in BMDM, suppression of PGE2 and PGD2 was evident. 
PGD2, acting on its receptors DP1 and DP2, is implicated in chemoattraction of TH2 cells, 
basophils, and eosinophils (Pettipher and Hansel 2008) and thus its suppression may also 
contribute to the altered microenvironment observed in COX-2MØKO tumors. 
 In previous studies, we showed a similar reduction in mammary tumorigenesis 
through deletion of COX-2 specifically from the mammary epithelial component 
(Markosyan, Chen et al. 2013) with a similar shift toward increased CD8+ CTL function. 
Due to the similarities in these experiments, there may be a possibility that deletion of 
macrophage COX-2, as in the current study, disrupts tumor cell COX-2 expression through 
loss of paracrine positive feedback, leading to an indirect recapitulation of MEC COX-2 
deletion. Indeed, deletion of COX-2 in orthotopic tumors led to an overall reduction in 
tumor COX-2 expression in COX-2MØKO hosts which could indicate reduced expression of 
COX-2 by cells other than macrophages (Figure 2-9C), and COX-2-induced COX-2 
expression has been shown in human ovarian cancers (Obermajer, Muthuswamy et al. 
2011, Obermajer, Muthuswamy et al. 2011). However, there are clear distinctions 
between MEC and macrophage COX-2 deletion that argue for independent functions of 
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COX-2 in mammary epithelium and macrophages during mammary tumorigenesis – 
enhanced CTL infiltration after MEC COX-2 deletion was associated with increased 
expression of T cell chemokine CXCL9 and reduced expression of PD-L1, while neither T 
cell chemokines nor PD-L1 expression were modified in COX-2MØKO tumors. Instead, 
reduced TAM infiltration and reduced immunosuppressive TAM function appear to be the 
dominant anti-tumorigeneic effects mediating enhanced CTL density in COX-2MØKO 
tumors. Thus, while both tumor cell and macrophage COX-2 can promote mammary 
tumorigenesis and regulate the composition of the tumor microenvironment, there are 
distinct functions of COX-2 in these separate tumor components. 
 Reduced TAM density in COX-2MØKO tumors was attributed to a similar reduction 
in expression of CSF-1R, the receptor for CSF-1, in macrophages that had not yet 
infiltrated tumor. Interestingly, CSF-1R expression in TAMs in the tumor was not altered 
between genotypes, which may indicate that a subset of macrophages that successfully 
infiltrate the tumor have sufficient expression of CSF-1R. Alternatively, tumor-derived 
signals within the TME may alter TAM phenotype such that differences in CSF-1R 
expression between genotypes are no longer evident. Concordantly, M2 polarization of 
WT BMDM, which simulates the M2-like phenotype of TAM, reduced expression of CSF-
1R to levels similar to M2 polarized COX-2MØKO BMDM. This suggests that comparison of 
CSF-1R expression in WT and COX-2MØKO TAM may not properly reflect differences in CSF-
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1R expression of macrophages prior to infiltration. 
 The studies in this Chapter support the concept that deletion of macrophage COX-
2 relieves TAM-mediated suppression of tumor infiltrating T cells, of which CD8+ CTLs are 
a primary effector of tumor growth suppression in COX-2MØKO mice. No change in tumor 
growth was observed after depletion of CD4+ T cells, which encompasses TH1, TH2, and 
TREGs, as compared to non-depleted mice in either genotype, which may reflect offsetting 
losses of pro-tumorigenic TH2/TREGs and anti-tumorigenic TH1 cells, negating any change 
in tumor growth. Interestingly, although the anti-tumorigenic functions of CTL are 
attributed to induction of apoptosis through caspase-dependent mechanisms, no change 
was observed in caspase-3 expression in orthotopic COX-2MØKO tumors compared to WT. 
It is possible that, since detection of caspase 3 gene expression in whole tumors does not 
discriminate between cell populations, divergent changes in expression were occurring 
between cell types – for example, tumor cell caspase-3 may be elevated because of CTL-
dependent apoptosis in COX-2MØKO tumors, while immunosuppressive TAM may induce 
T cell apoptosis (Badley, Dockrell et al. 1997, Saio, Radoja et al. 2001) in WT tumors. 
Alternatively, CTL-mediated perforin-granzyme A and granzyme B pathways can mediate 
apoptosis through DNA damage without activating caspase pathways (Trapani, Jans et al. 
1998, Trapani and Smyth 2002). 
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 A supportive TME is essential for tumor progression towards malignancy. Immune 
cells, which may initially infiltrate the tumor with the goal of tumor cell destruction, can 
be hijacked by tumor cells to instead suppress anti-tumor immunity and enhance tumor 
growth. Importantly, the phenotype of distinctly polarized or differentiated immune cells 
can dictate its effector functions in tumors, which can be either anti- or pro-tumorigenic. 
Clinical studies augmenting CTL responses through antibody-mediated inhibition of T cell 
co-inhibitory molecules PD-L1 and CTLA-4, have shown promising results in certain 
cancers, indicating that the pro-tumorigenic TME of established tumors may be 
conditioned to enhance anti-tumor immunity (Topalian, Hodi et al. 2012, Mocellin and 
Nitti 2013).  Further, a stromal signature indicating high TAM and low CTL density has 
been proposed as an indicator of poor prognosis in human breast cancers (Finak, Bertos 
et al. 2008). The studies in this Chapter suggest an important role for macrophage COX-2 
in modifying the TME in breast cancer, such that its deletion can mediate reduced 
HER2/neu-driven mammary tumorigenesis in mice. These data may indicate that targeted 
inhibition of macrophage COX-2 may provide an approach to enhance tumor immune 
surveillance. As macrophages are a tractable target for nanotherapeutic delivery, in 
Chapter 4 we discuss and investigate the use of nanoparticles as a vehicle for targeted 
COX-2 inhibitor delivery to achieve the anti-tumor benefit of COX-2 inhibitors without the 
side effects of systemic inhibition.  
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CHAPTER 3 : PARACRINE AND AUTOCRINE CONTRIBUTIONS OF COX-2 IN 
MACROPHAGE POLARIZATION 
3.1 Introduction 
Macrophages, long considered an integral part of innate immunity and host 
defense, also have important roles in wound healing, tissue remodeling, resolution of 
inflammation, angiogenesis, and other homeostatic functions (Laoui, Movahedi et al. 
2011, Sica and Mantovani 2012). Macrophage function and phenotype can vary 
depending on external stimuli, including cytokines, lipid mediators, and co-inhibitory or 
co-stimulatory molecules (Mantovani, Sozzani et al. 2002, Sica, Schioppa et al. 2006). A 
useful paradigm in classifying macrophage phenotypes focuses on a dichotomy between 
classically-activated (“M1 polarized”) macrophages, stimulated in vitro using TLR ligands 
and IFNγ, and alternatively-activated (“M2 polarized”) macrophages, stimulated with IL-
4 and IL-13 (Gordon 2003). Cell surface markers, cytokines, and enzymes differentially 
expressed between M1 and M2 polarized macrophages have been helpful in classifying 
macrophages within a pathological setting as either M1- or M2-like macrophages, 
particularly when it proves difficult to establish in vivo function through ex vivo analysis. 
In reality, however, M1 and M2 polarization represent extremes in a continuum of 
macrophage phenotypes. Under physiological and pathophysiological conditions, 
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macrophages can adopt a range of phenotypes, thereby playing distinct and often 
divergent functional roles conditioned on the activation state (Sica and Mantovani 2012). 
In cancer, M1 macrophages are considered anti-tumorigenic due to their production of 
cytotoxic RNS, efficient antigen-presenting capabilities, and release of type 1 cytokines, 
such as TNFα, which can induce and promote immune cell-mediated tumor rejection (Doe 
and Henson 1978, Taffet and Russell 1981). M2 macrophages, on the other hand, are 
considered pro-tumorigenic because, through elevated expression of arginase-1, they 
deplete the extracellular environment of arginine, an amino acid essential for RNS 
generation, leading to T cell anergy and immunosuppression (Chang, Liao et al. 2001, 
Rodriguez, Quiceno et al. 2004). Further, M2 macrophages release growth promoting 
amino acids (such as L-ornithine) and support angiogenesis and extracellular matrix 
remodeling (Sica, Schioppa et al. 2006). In general, tumor-associated macrophages 
(TAMs) more closely resemble M2 macrophages in that they are poor producers of RNS, 
promote tumor cell proliferation (Dinapoli, Calderon et al. 1996), and are efficient 
scavengers of cell debris with poor antigen-presenting abilities (Mantovani, Bottazzi et al. 
1992). Given these functional characteristics, it is unsurprising that increased TAM density 
associates with poor prognosis in human cancers (Lewis and Pollard 2006), and 
experimental macrophage depletion reduces primary or metastatic tumor growth in 
preclinical cancer models (Lin, Li et al. 2006, Qian, Deng et al. 2009). 
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 Although the paradigm that M1 macrophages are anti-tumorigenic and M2 
macrophages are pro-tumorigenic is generally well accepted in established tumors, some 
have hypothesized that the opposite may be true at certain stages of tumor development 
(Bogels, Braster et al. 2012). In particular, prolonged M1 macrophage activation or 
dysregulation may promote tumor initiation through uncontrolled inflammation, 
excessive recruitment of immune cells, and increased cellular destruction leading to 
genetic instability (Van Ginderachter, Movahedi et al. 2006). Conversely, the resolving 
functions of M2 macrophages may be beneficial by limiting tumor inflammation. These 
contextual complexities add to the challenges of targeting specific macrophage 
phenotypes at different stages of tumor onset and progression. Further, TAMs are plastic 
and may selectively adopt pro-tumor M1 or M2 macrophages as influenced by their 
immediate microenvironment within the tumor (Sica and Mantovani 2012). To 
successfully approach TAM as a therapeutic target, it is essential to fully understand local 
influences on macrophage phenotype and function. 
 PGE2, the major product of COX-2 in tumors (Greenhough, Smartt et al. 2009), is 
typically associated with suppression of the M1 macrophage phenotype and enhanced 
M2 polarization. However, PGE2 has been predominantly studied in the context of 
exogenous PGE2 added in vitro to macrophages activated with LPS as an inflammatory 
stimulus (Chen and Smyth 2011). Less attention has been paid to M1 or M2 polarized 
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macrophages or the influence of macrophage-derived PGE2 as an autocrine regulator of 
macrophage function. Further, the effect of other prostaglandins on macrophage 
polarization has not been well studied. Through activation of EP2/EP4 receptors and 
increased cAMP (Katsuyama, Ikegami et al. 1998), exogenous PGE2 suppressed release of 
several M1 cytokines in LPS-stimulated human and murine macrophages, including IL-1β, 
TNFα, IL-6, and IL-8 (Knudsen, Dinarello et al. 1986, Bailly, Ferrua et al. 1990, Standiford, 
Kunkel et al. 1992). Further, exogenous PGE2 enhanced production of IL-10 and increased 
expression of arginase-1, both of which are M2 markers, in unstimulated murine 
macrophages (Strassmann, Patil-Koota et al. 1994, Wu, Llewellyn et al. 2010). Reduced 
M2 macrophage polarization, defined as an enhanced antigen-presenting phenotype in 
mouse bone marrow-derived myeloid cells (Eruslanov, Daurkin et al. 2010) or, in a study 
of human peripheral blood monocytes, as reduced expression of CD163 (Na, Yoon et al. 
2013), with pharmacological COX-2 inhibition suggests an autocrine influence of COX-2-
derived mediators in controlling macrophage phenotype. As discussed in the previous 
Chapter, evidence for altered TAM polarization was evident with deletion of paracrine 
(mammary epithelial cell) or autocrine (macrophage) sources of COX-2. The studies in this 
Chapter explored in greater depth the paracrine and autocrine influences of COX-2-
derived mediators on macrophage phenotype in the context of M1 and M2 polarization 
using pharmacological and genetic approaches to COX-2 interruption. The results of these 
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studies highlight the complexities of modeling a multifactorial microenvironment in vitro 
and may provide an important framework for considering macrophage phenotype when 
targeting COX-2 in tumorigenesis. 
3.2 Experimental Procedures 
3.2.1 Bone Marrow-Derived Macrophage Isolation, Culture, and Treatments 
Mouse backgrounds and genotypes, and isolation and culture of BMDM, are 
described in the previous Chapter. For macrophage polarization experiments, BMDM 
were plated at 3 x 105 cells per 60mm2 dish in 4mL LCCM. After 24 hours of culture, LCCM 
was replaced with serum free medium. In experiments with COX-2 inhibitors, 1μM 
rofecoxib (Sigma-Aldrich, #SML0613) or DMSO was added to dishes after 6 hours of serum 
starvation. BMDM were polarized using an M1 cytokine cocktail (20 ng/mL IFNγ, 
Peprotech, #315-05 and 100 ng/mL LPS, Sigma-Aldrich, #L4391), M2 cytokine cocktail (20 
ng/mL IL-4, Peprotech, #214-14 and 10 ng/mL IL-13, Peprotech, #210-13), or water (“M0”) 
as control with simultaneous stimulation with different concentrations of PGE2 (Cayman 
Chemicals, #14010) or DMSO as control. After 6 hours (for M1) or 18 hours (for M0 and 
M2), BMDM were lysed for mRNA isolation (RNeasy Mini Kit, Qiagen, #74106) for gene 
expression analysis by Q-PCR.  
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3.2.2 Quantitative-PCR 
RNA isolated from BMDM was quantified (NanoDrop Spectrophotometer) and 
reverse transcribed into cDNA (MultiScribe Reverse Transcriptase, Life Technologies, 
#4311235) according to manufacturer’s instructions. Quantitative real-time polymerase 
chain reaction (Q-PCR) of cDNA was carried out using inventoried primer/probe gene 
expression assays with TaqMan Universal PCR Master Mix (Life Technologies, #4304437) 
for all genes. Q-PCR products were monitored using the ViiaTM 7 Real-Time PCR System 
(Applied Biosystems) and data was analyzed using the 2-ΔΔCt method of relative 
quantification (RQ) (Bookout and Mangelsdorf 2003) using 18S for normalization and 
mixed M1/M2 polarized macrophage RNA as a calibrator.  
3.2.3 Mass Spectrometry 
 Detection of prostaglandins in cell culture supernatants is discussed in the 
previous chapter. Prostaglandins are normalized to total mRNA isolated from tissue, as 
detected using a NanoDrop Spectrophotometer. 
3.2.4 Statistical Analysis 
 All significance testing was performed with non-parametric two-sample Mann-
Whitney tests following significant two-way ANOVA.  Paired tests were performed when 
appropriate. Statistical analyses were performed using Prism (GraphPad Software). 
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Handling of multiple testing was done through estimation of the number of false 
positives. A total of 256 two-sample tests were performed, with a significance threshold 
of 0.05. A total of 85 of the 256 p-values are significant at the 0.05 level.  We therefore 
would expect 0.05 * 256 = 12.8 false positives from 256 tests if all null hypotheses were 
true.  Thus we (conservatively) expect approximately 72 of our rejected null hypotheses 
to be correctly rejected.  With 72 true positives, the expected number of falsely rejected 
null hypotheses falls to 0.05 * 184 = 9.2.  Therefore we can (conservatively) expect ten 
false positives from the 85 rejected null hypotheses.  This number is still conservative 
since many of the observed p-values are very small.  The overall conclusions of this 
Chapter are robust to a small number of false positives, particularly among the 
hypotheses with marginal p-values. 
3.3 Results 
3.3.1 Changes in COX Pathway Protein Expression by PGE2 in Polarized Macrophages 
 Functional coupling of COX-1 to cytosolic (c) PGES and COX-2 to mPGES-1 has been 
described (Murakami, Naraba et al. 2000, Tanioka, Nakatani et al. 2000), as has a positive 
feedback influence of PGE2 to further induce its own production by augmenting COX-2 
and mPGES-1 expression (Murakami, Naraba et al. 2000, Obermajer, Muthuswamy et al. 
2011). However, regulation of COX pathway enzymes during macrophage polarization, 
and feedback regulation by PGE2, has not been described. We performed Q-PCR on M1 
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or M2 polarized WT BMDM with and without exogenous PGE2 treatment.  
Treatment of WT BMDM with M1 polarizing cytokines (IFNγ and the TLR4 agonist 
LPS) greatly suppressed COX-1 expression and enhanced COX-2 and mPGES-1 expression 
(Figure 3-1A-C), consistent with pro-inflammatory M1 functions. Further, M1 polarization 
greatly suppressed expression of the PGE2 metabolizing enzyme 15-PGDH (Figure 3-1D), 
without altering uptake (PGT) or export (MRP4) transporter expression (Figure 3-1E,F). 
Expression of other prostanoid synthases TxA2 synthase and PGD2 synthase (Figure 3-
1G,H) were reduced, likely further favoring AA metabolism to PGE2 (other synthases were 
minimally detected). Exogenously added PGE2 significantly, but minimally, enhanced COX-
1 expression at the highest concentration used, although the M1-associated suppression 
of COX-1 continued to dominate. M1-augmented COX-2 and mPGES-1 expression were 
either sustained or further enhanced by exogenous PGE2 (Figure 3-1A-C). Addition of PGE2 
did not significantly modify the already strongly M1-suppressed expression of 15-PGDH, 
though expression of PGT was reduced and MRP4 augmented by PGE2 treatment of M1-
macrophages (Figure 3-1D-F). Thus, paracrine PGE2 may act to reduce its own degradation 
and enhance its own transport to the extracellular space under M1 polarizing conditions. 
In general, the effects of PGE2 on COX pathways enzymes and transporters were minor in 
unpolarized BMDM, although suppression of 15-PGDH, PGT and TXAS were apparent 
even in the unstimulated macrophages (Figure 3-2).  
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The impact of M2 polarizing cytokines (IL-4 and IL-13) was generally opposite to 
M1. Thus, COX-1 expression was enhanced while COX-2 expression was reduced, with no 
change in mPGES-1 mRNA levels (Figure 3-3A-C). Similar to M1 polarization, 15-PGDH 
mRNA was reduced, and transport proteins unchanged by M2 cytokines (Figure 3-3D-F). 
Reduced expression of H-PGDS was also evident under M2 conditions although in contrast 
to M1, TXAS was elevated (Figure 3-3G,H). Interestingly, exogenous PGE2 restored COX-2 
and enhanced mPGES-1 expression, while 15-PGDH remained suppressed (Figure 3-3B-
D), indicating that in M2 conditions, as in M1 conditions, PGE2 positively regulates its own 
biosynthesis (Figure 3-1B-D).  
Taken together, these data indicate opposing influences of M1 and M2 
polarization on PGE2 biosynthesis, with M1 conditions favoring enhanced PGE2 
generation. Indeed, PGE2 production was significantly increased after addition of M1 
cytokines. Concordant with modest COX-1 induction and suppressed COX-2 expression, 
low levels of prostanoids were generated by M2 polarized macrophages (Figure 3-4B). 
Regardless of the polarizing conditions, exogenous PGE2 positively impacted its own 
biosynthesis.  
3.3.2 Paracrine PGE2 Modifies M1 and M2 Macrophage Polarization 
As expected, M1 cytokine treatment of WT BMDM strongly induced  
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Figure 3-1 Expression of COX pathway enzymes and transporters in M1 BMDM stimulated with PGE2.  
Treatment with M1 polarizing cocktail (20 ng/mL IFNγ + 100 ng/mL LPS, 6 hrs) suppressed expression of (A) COX-1, (D) 
15-PGDH, (G) TxAS, and (H) H-PGDS. Expression of (B) COX-2 and (C) mPGES-1 were increased while transport enzymes 
(E) PGT and (F) MRP4 were unchanged. Co-treatment with exogenous PGE2 dose-dependently (C) increased mPGES-1 
expression and (G) decreased TxAS expression. Data are mean ± SEM, expressed as fold change of treatment ΔCt vs. 
M1 ΔC, n=4-16. +vs. No Treatment, No PGE2, *vs. M1 Cytokines, No PGE2. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 3-2 Expression of COX pathway enzymes and transporters in unpolarized BMDM stimulated with PGE2.  
COX pathway enzyme and transporter expression was minimally changed in response to PGE2 (18hrs). Data are mean 
± SEM, expressed as fold change of treatment ΔCt vs. M0 ΔCt. +vs. No Treatment, No PGE2, n=4. +p<0.05, ++p<0.01, 
+++p<0.001. 
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Figure 3-3 Expression of COX pathway enzymes and transporters in M2 BMDM stimulated with PGE2.  
Treatment with M2 polarizing cytokines (20 ng/mL IL-4 + 10 ng/mL IL-13, 18hrs) suppressed (B) COX-2, (D) 15-PGDH, 
and (H) H-PGDS expression while enhancing (A) COX-1 and (G) TxAS expression. Co-treatment with exogenous PGE2 
dose-dependently increased (B) COX-2 and (C) mPGES-1 expression. Data are mean ± SEM, expressed as fold change of 
treatment ΔCt vs. M2 ΔCt. +vs. No Treatment, No PGE2, *vs. M2 Cytokines, No PGE2, n=4-14. *p<0.05, **p<0.01, 
***p<0.001. 
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Figure 3-4 Prostaglandin production by polarized BMDM.  
M1 polarization (20 ng/mL IFNγ + 100 ng/mL LPS, 6 hrs) significantly increased BMDM generation of (B) PGE2, but not 
other prostaglandins (in (A) the increase in PGD2 was non-significant). M1 production of (C) PGI2 and (D) TxA2 
metabolites were unchanged as compared to unpolarized BMDM (18 hrs). (A-D) M2 polarization (20 ng/mL IL-4 + 10 
ng/mL IL-13, 18 hrs) did not significantly alter production of prostaglandins from baseline. Data are mean ± SEM, n=4. 
*p<0.05. 
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expression of M1 markers iNOS, TNFα, IL-6, and CD86 (Figure 3-5A-D) with a modest 4-
fold induction of arginase-1 (Figure 3-5E), while treatment of M2 cytokines suppressed 
TNFα and CD86 with a strong 12.5-fold induction of arginase-1 (Figure 3-6A-E). 
Concordant with published investigations of PGE2’s influence on LPS-stimulated 
macrophages, TNFα and CD86 expression in M1 macrophages were dose dependently 
suppressed by exogenous PGE2, although no consistent changes were observed in IL-6 
expression (Figure 3-5B-D). Interestingly, PGE2 augmented expression of both iNOS and 
arginase-1 under M1 conditions, indicating that paracrine acting COX-2 products can 
substantially mobilize arginine metabolism (Figure 3-5A,E). Under M2 polarizing 
conditions, while TNFα and iNOS were unchanged with PGE2 treatment, expression of IL-
6 and CD86, both typically considered M1 inflammatory markers, were enhanced by PGE2 
(Figure 3-6A-D). Further, as observed under M1 conditions, PGE2 strongly augmented 
arginase-1 expression well above levels observed with M2 polarization alone, supporting 
a role for paracrine PGE2 in promoting immune suppressive functions of M2 macrophages 
(Figure 3-6E). M2-mediated suppression of CD86, a molecule that can either activate or 
inhibit T cells dependent on the receptor encountered on the T cell surface (CD28 and 
CTLA-4, respectively) (Slavik, Hutchcroft et al. 1999), was restored and further augmented 
by exogenous PGE2. As above, exogenous PGE2 did not consistently alter expression of 
either M1 or M2 markers in the absence of polarizing cytokines (Figure 3-7), suggesting  
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Figure 3-5 Expression of M1 and M2 markers of polarization in M1 BMDM stimulated with PGE2. 
Treatment with M1 polarizing cocktail (20 ng/mL IFNγ + 100 ng/mL LPS, 6 hrs) enhanced expression of M1 markers (A-
D) iNOS, TNFα, IL-6, and CD86 and M2 marker (E) arginase-1. Co-treatment with exogenous PGE2 led to dose-dependent 
increases in (A) iNOS and (E) arginase-1 expression while suppressing expression of (B) TNFα and (D) CD86. Data are 
mean ± SEM, expressed as fold change of treatment ΔCt vs. M1 ΔC, n=4-16. +vs. No Treatment, No PGE2, *vs. M1 
Cytokines, No PGE2, n=7. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 3-6 Expression of M1 and M2 markers of polarization in M2 BMDM stimulated with PGE2. 
Treatment with M2 polarizing cytokines (20 ng/mL IL-4 + 10 ng/mL IL-13, 18 hrs) suppressed (B) TNFα 
and (D) CD86 expression and enhanced (E) arginase-1 expression. Co-treatment with exogenous PGE2 
dose-dependently (C-E) increased IL-6, CD86, and arginase-1 expression. Data are mean ± SEM, 
expressed as fold change of treatment ΔCt vs. M2 ΔCt. +vs. No Treatment, No PGE2, *vs. M2 Cytokines, 
No PGE2, n=4-6. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 3-7 Expression of M1 and M2 markers of polarization in unpolarized BMDM stimulated with PGE2. 
Stimulation of unpolarized BMDM with PGE2 (18 hrs) did not significantly alter expression of (A-E) M1 or M2 
polarization markers. Data are mean ± SEM, expressed as fold change of treatment ΔCt vs. M0 ΔCt, n=4. 
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Summary of Changes in Gene Expression after Macrophage Polarization 
 M1 M2 
 Control PGE2 Control PGE2 
COX-1 ↓ = ↑ ↑ 
COX-2 ↑ ↑ ↓ ↑ 
mPGES-1 ↑ ↑ = ↑ 
15-PGDH ↓ = ↓ = 
PGT = = = = 
MRP4 = ↑ = = 
iNOS ↑ ↑ = = 
TNFα ↑ ↓ ↓ = 
IL-6 ↑ = = ↑ 
CD86 ↑ ↓ ↓ ↑ 
Arginase-1 ↓ ↑ ↑ ↑ 
Table 3-1 Summary of changes in gene expression after BMDM polarization.  
M1 Control and M2 Control columns, ↑ represents increase in expression, ↓ represents decrease in expression, 
and = represents no change in expression vs. unpolarized BMDM. In M1 + PGE2 and M2 + PGE2 columns, ↑ 
represents increase in expression, ↓ represents decrease in expression, = represents no change in expression, and 
vs. M1 or M2 polarized BMDM, respectively.  
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that PGE2 primarily contributes a modulatory role in cytokine-driven macrophage 
polarization. 
 These data indicate that while exogenous PGE2 restrains some inflammatory 
mediators (e.g. TNFα), but not others (e.g. IL-6, iNOS), a dominant effect to augment the 
immunosuppressive M2 macrophage phenotype (i.e. enhanced arginase-1) was evident, 
regardless of whether cells are under M1 or M2 polarizing conditions (summarized in 
Table 3-1).  
3.3.3 COX-2 Inhibition in Polarized Macrophages  
The studies outlined above examined how exogenous PGE2, a model of paracrine 
regulation of macrophage function, influenced macrophage phenotypic markers and COX 
pathway enzyme and transporter expression during macrophage polarization. As outlined 
above, PGE2 is a major macrophage product and its biosynthetic and degradation 
pathways are responsive to M1 and M2 cytokines and, in turn, to PGE2 itself. We next 
examined, therefore, the autocrine effect of macrophage-derived COX-2 products. 
BMDM were isolated from mice with selective deletion of COX-2 in macrophages (COX-
2MØKO mice; see Chapter 2 for a full description). As expected, COX-2 expression, which 
was evident under M1 conditions, was significantly reduced in COX-2MØKO BMDM 
compared to WT BMDM (Figure 3-8B). Interestingly, M1 induction of COX-2 was equally 
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offset by pharmacological COX-2 inhibition with rofecoxib in WT BMDM, and combined 
genetic and pharmacological inhibition rendered COX-2 essentially unresponsive to M1 
cytokine treatment, suggesting that positive product feedback, likely by PGE2, is key to 
COX-2 upregulation in classically activated inflammatory macrophages. No change in 
COX-2 expression was observed in M2 polarized WT or COX-2MØKO BMDM, likely because 
of the already low expression of COX-2 in untreated and M2 polarized macrophages 
(Figure 3-9B). In contrast, expression of other COX pathway components, including the 
enzymes COX-1, mPGES-1, and 15-PGDH and transport proteins PGT and MRP4, were not 
consistently altered by genetic COX-2 deletion or pharmacological inhibition with 
rofecoxib in either the M1 or M2 setting (Figure 3-8,9).  
 Deletion of COX-2 from macrophages did not alter their response to M1 cytokines 
– iNOS, TNFα, IL-6, and CD86 were not different between M1 polarized WT vs COX-2MØKO 
BMDM (Figure 3-10). Similarly, except for a modest effect on IL-6 expression, 
pharmacological inhibition of COX-2 did not markedly impact M1 marker expression 
(Figure 3-10B). M2 polarized COX-2MØKO BMDM revealed no significant differences in 
expression of M2 markers arginase-1, RELMα, and Ym1, though there was considerable 
variability between samples (Figure 3-11). Thus, it appeared that autocrine PGE2 was 
substantially less relevant to macrophage polarization and phenotype compared to 
paracrine (exogenous) PGE2.  
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Figure 3-8 Expression of COX pathway enzymes and transporters in M1 BMDM after COX-2 inhibition or 
genetic deletion.   
Expression of (B) COX-2 was significantly decreased after genetic deletion (COX-2MØKO BMDM) or 
pharmacological inhibition (1μM rofecoxib) of COX-2. Rofecoxib-treated COX-2MØKO BMDM had further 
suppressed COX-2 expression. (A,C-F) Expression of other COX pathway enzymes and transporters were not 
significantly changed in M0 or M1 polarized COX-2MØKO BMDM as compared to WT BMDM, or in rofecoxib-
treated M1 polarized WT BMDM compared to untreated M1 polarized WT BMDM. Data are mean ± SEM, n=7. 
*vs. M1 polarized WT BMDM, +vs. M1 polarized COX-2MØKO BMDM. **p<0.01, +++p<0.001. 
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Figure 3-9 Expression of COX pathway enzymes and transporters in M2 BMDM after COX-2 inhibition or genetic 
deletion.   
Expression of COX pathway enzymes and transporters were not significantly changed in M0 or M2 polarized COX-
2MØKO BMDM as compared to WT BMDM, or in rofecoxib-treated M1 polarized WT BMDM compared to untreated 
M2 polarized WT BMDM. Data are mean ± SEM, n=7. 
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Figure 3-10 Expression of M1 markers in M1 polarized BMDM after COX-2 inhibition or genetic deletion.  
Expression of M1 macrophage markers were not significantly altered in M0 or M1 polarized COX-2MØKO BMDM as 
compared to WT BMDM, or in rofecoxib-treated M1 polarized WT BMDM compared to untreated M1 polarized WT 
BMDM. However, (B) rofecoxib treatment of M1 polarized COX-2MØKO BMDM reduced expression of IL-6 as compared 
to untreated COX-2MØKO BMDM. Data are mean ± SEM, n=6. +vs. M1 polarized COX-2MØKO BMDM. +p<0.05. 
Figure 3-11 Expression of M2 markers in M2 polarized BMDM after COX-2 inhibition or genetic deletion.  
Expression of M2 macrophage markers were not significantly altered in M0 or M2 polarized COX-2MØKO BMDM as 
compared to WT BMDM, or in rofecoxib-treated M2 polarized WT BMDM compared to untreated M2 polarized WT 
BMDM. Data are mean ± SEM, n=8. 
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3.4 Discussion 
 Tumor-associated macrophages are classified as having an M2-like macrophage 
phenotype due to high arginase-1 expression, leading to suppression of anti-tumor 
immune response, poor antigen-presenting capabilities, and a reduction in type 1 
cytokine release, such as TNFα and IL-1β (Mantovani, Sozzani et al. 2002). However, M2 
macrophage polarization, at least as defined in vitro, does not fully recapitulate the TAM 
phenotype. Of particular interest to our studies, TAM express significant levels of COX-2 
(Klimp, Hollema et al. 2001, Nakao, Kuwano et al. 2005, Biswas, Sica et al. 2008). However, 
M2 polarizing cytokines actually suppressed COX-2 expression in BMDM (Figure 3-3B). 
Indeed, as for LPS-stimulated macrophages (Hui, Ricciotti et al. 2010), robust upregulation 
of COX-2 expression (and subsequent PGE2 generation)  is characteristic of the M1 
phenotype. Thus, the caveat of TAM being “M2-like” rather than standard M2 includes a 
discrepancy in COX-2 expression. Interestingly, treatment of BMDM with exogenous PGE2 
during M2 polarization, to model the paracrine influence of tumor-derived PGE2, reversed 
M2 cytokine-mediated suppression of COX-2 expression (Figure 3-3B), while also 
enhancing arginase-1 levels far above levels observed with M2 polarizing cytokines alone 
(Figure 3-6E). Further, under M1 conditions, exogenous PGE2 dose-dependently 
suppressed expression of M1 phenotypic markers, but the COX-2-mPGES-1 pathway 
remained high (Figure 3-1) and arginase-1 was induced (Figure 3-5). These experiments 
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reveal a PGE2-dependent modification of macrophage phenotype in which, regardless of 
polarization state, BMDM more closely resemble TAM, at least as defined by these 
markers (Table 3-2). Thus, while under the influence of PGE2 plus either M1 or M2 
polarizing cytokines, BMDM display low expression of inflammatory cytokines, high 
expression of arginase-1, and elevated expression of COX-2. These conditions may mirror 
the TME, where tumor cells provide a paracrine source of PGE2 that redirect infiltrating 
M1 macrophages from an inflammatory phenotype to the M2-like phenotype 
characteristic of TAM. Further, once re-polarized to the M2-like state, PGE2 would be 
expected to amplify certain functions of TAM (such as expression of immunosuppressive 
arginase-1), while maintaining enhanced COX-2 expression. These studies suggest that 
PGE2 is an essential paracrine-derived mediator in determining TAM phenotype and 
immunosuppressive function, a conclusion that is consistent with reduced M2 marker 
expression in COX-2MECKO tumors (Figure 1-8D) (Markosyan, Chen et al. 2013). 
 Interestingly, in the absence of polarizing cytokines, PGE2-mediated modulation 
of macrophage phenotype is absent (Figure 3-2,7), suggesting a requirement of 
macrophage activation before responsiveness to PGE2. This may be due to changes in 
prostanoid receptor expression or COX enzyme expression that amplify the response to 
PGE2 during macrophage polarization. Under M1 polarizing conditions, changes in 
expression of 15-PGDH and transport enzymes PGT and MRP4 in response to PGE2 suggest  
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PGE2 Modifies Polarized Macrophage Phenotype to Resemble TAM 
 M1 M1 + PGE2 M2 M2 + PGE2 TAM 
COX-2 ↑ ↑ ↓ = ↑ 
TNFα ↑ ↓ ↓ ↓ ↓ 
Arginase-1 ↑ ↑↑↑ ↑ ↑↑↑ ↑↑↑ 
Table 3-2 PGE2 modifies polarized macrophage phenotype.  
Addition of exogenous PGE2 concurrent with M1 or M2 polarizing cytokines leads to a modification in gene 
expression such that polarized BMDM more closely resemble a TAM-like phenotype. ↑ represents high expression, 
↑↑↑ represents very high expression, ↓ represents low expression, and = represents equivalent expression as 
compared to unpolarized BMDM. 
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a coordinated effort to maintain high extracellular levels of PGE2 that would be expected 
to increase PGE2 efflux, and decrease PGE2 influx, possibly reinforcing the positive 
feedback by exogenous PGE2 on COX-2 expression. Indeed, under M2 conditions, though 
expression of transport proteins was minimally affected, 15-PGDH expression was further 
reduced at some concentrations of PGE2, highlighting a possible role of tumor cell-derived 
PGE2 to maintain PGE2 levels further supporting immunosuppression and tumorigenesis.  
 CD86 is a ligand for two proteins (CD28 and CTLA-4) that work in opposition to 
activate or suppress T cells, respectively (Slavik, Hutchcroft et al. 1999). Under conditions 
of high expression of the co-stimulatory molecule CD28, enhanced CD86 expression 
would promote T cell activation, while high CTLA-4 would, conversely, attenuate immune 
function. Interestingly, exogenous PGE2 suppressed CD86 expression in M1 macrophages 
but augmented CD86 expression in M2 macrophages. It may be that this divergent 
regulation of CD86 by PGE2 reflects suppression of inflammatory macrophage support of 
T cell immune functions under M1 polarizing conditions but enhanced M2 macrophage 
immunosuppressive function under M2 polarizing conditions.  
Expression of TXAS and H-PGDS was also significantly altered in response to M1 
and M2 polarization. To investigate a possible role of other prostaglandins in determining 
macrophage phenotype, we studied the effects of several prostaglandin receptor agonists 
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on M1 and M2 macrophage polarization in RAW 264.7 macrophage-like cells. Under M1 
polarizing conditions, PGE2, DP2 agonist DK-PGD2, and IP agonist cicaprost significantly 
reduced expression of TNFα, which was used as a marker of M1 macrophage polarization. 
Interestingly, under M2 polarizing condition, PGE2 was the lone mediator that 
consistently augmented expression of arginase-1. In fact, TP agonist U46619 and DP2 
agonist DK-PGD2 suppressed arginase-1 expression. Thus, while several prostanoids may 
mediate reduced M1 macrophage polarization, only PGE2 enhances arginase-1 
expression.  
In contrast to exogenous PGE2, suppression of autocrine PGE2, by deletion of 
macrophage COX-2, minimally altered expression of a majority of M1 and M2 polarization 
markers (Figure 3-11,12). Interestingly, although statistical significance was not reached, 
several M2 markers (i.e. arginase-1, RELMα, Ym1) seemed to be enhanced in COX-2MØKO 
BMDM, but not in rofecoxib-treated BMDM. This may indicate distinct effects of 
pharmacological inhibition and genetic deletion of COX-2 in determining macrophage 
polarization, a notion that may warrant further investigation. It should be noted, 
however, that LysM-Cre mediated deletion of macrophage COX-2 may be incomplete. 
Indeed, treatment of M1 polarized COX-2MØKO BMDM with rofecoxib further suppressed 
expression of COX-2 mRNA, indicating residual COX-2 expression in the COX-2MØKO cells. 
It is possible, however, that contamination of other cells in the BMDM culture provide an 
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additional source of COX-2 (by flow cytometry, approximate F4/80+CD11b+Gr-
1- positivity, indicating macrophages, of BMDM was >95%). Overall, the lack of substantial 
changes in macrophage polarization with COX-2 deletion or rofecoxib treatment indicates 
a minimal role of autocrine COX-2 in determining macrophage phenotype, at least in vitro. 
These studies may seem contradictory to published studies that suggest reduction in 
inflammatory characteristics of LPS-stimulated macrophages after COX-2 inhibition 
(Callejas, Fernandez-Martinez et al. 2003). Notably, in the M1 paradigm used in the 
studies outlined in this Chapter, the concentration of LPS is 50-fold lower than that 
typically used in LPS-mediated macrophage stimulation. Thus, though COX-2 inhibition 
may reduce expression of certain M1 markers in the context of strong LPS activation of 
macrophages, COX-2 inhibition and deletion does not strongly alter M1 marker 
expression in the context of M1 polarization. Further, COX-2MØKO BMDM does not 
recapitulate the phenotypic changes in COX-2MØKO TAM observed in the tumor models 
described in Chapter 2 (i.e. reduced arginase-1, Figure 2-17). This discrepancy highlights 
the challenges in modeling TAM, which are influenced by the complex multi-cellular and 
multi-mediator TME, using in vitro polarized macrophages. In particular, WT TAM may 
have severely enhanced M2 characteristics, above levels seen after in vitro M2 
polarization, making reductions in M2 marker expression in COX-2MØKO TAM more 
apparent than in COX-2MØKO BMDM. These studies stress caution in accepting 
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conclusions based on in vitro models as mechanistic determinations of in vivo 
phenotypes, particularly for biological processes as complex as macrophage polarization 
and TME. Further, preliminary evidence in this Chapter comparing genetic macrophage 
COX-2 deletion to pharmacological COX-2 inhibition raises the notion that the distinct 
approaches to COX-2 suppression may yield different outcomes. Thus, targeted therapies 
utilizing pharmacological inhibitors (such as celecoxib) and genetic knockdown (such as 
COX-2 siRNA) may yield different results and investigation of both, confirming the desired 
outcome, is warranted. 
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CHAPTER 4 : INVESTIGATION OF MACROPHAGE TARGETED COX-2 
INHIBITORS 
4.1 Introduction 
 COX-2 inhibitor use is associated with reduced risk in a number of cancers (REF). 
However, the clinical utility of systemic COX-2 inhibition in cancer prevention and therapy 
is severely limited because of an established cardiovascular risk with this class of drugs 
(Grosser, Yu et al. 2010). Importantly, the mechanisms that underlie the anti-tumor 
effects of COX-2 inhibitors are distinct from those driving elevated cardiovascular risk. 
Thus, the anti-tumor benefit arises from inhibition of COX-2-derived PGE2 generation in 
tumors while loss of vascular endothelial COX-2-derived PGI2, an antiplatelet 
cardioprotective mediator, is responsible for elevated cardiovascular risk. The latter is not 
necessary for the former, providing opportunities for targeted therapies that realize the 
anti-tumor benefit while avoiding the side effects of systemic COX-2 inhibition. Further, 
because of improved pharmacokinetics and concentrated treatment delivery to the 
diseased area, targeted drug therapies may allow for lower overall dosage, further 
reducing side effects, and/or enhancing drug efficacy. The demonstration of reduced 
tumorigenesis in COX-2MØKO mice (Figure 2-3,9), that is at least equivalent to COX-2 
deletion in tumor cells (Figure 1-4) and systemic pharmacological COX-2 inhibition (Lanza-
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Jacoby, Miller et al. 2003) provides a solid rationale for targeting macrophage COX-2 in 
breast cancer.  
 Nanoparticles (NP), which employ nanomaterials (typically less than <100nm in 
one dimension), provide several unique benefits over conventional drugs. NPs have 
longer circulation half-life due to stealth polymerization by PEG particles that prevent 
interaction with plasma proteins, and thus have improved distribution over free 
therapeutic agents (Wang and Thanou 2010). Further, the larger surface-to-mass ratio of 
NPs provides enhanced targeting through addition of cell surface recognition molecules 
allowing for optimized delivery to target sites (Mout, Moyano et al. 2012). The 
development of NPs is highly sophisticated and involves optimization of several 
characteristics such as size, stability, drug loading, drug release, and, of course, analysis 
of therapeutic benefit and toxicity (Lameijer, Tang et al. 2013). Interestingly, 
macrophages are an attractive target for NPs because they actively seek and phagocytize 
foreign particles. In fact, NPs are typically engineered to evade macrophages (Lameijer, 
Tang et al. 2013). Further, because of unique macrophage phenotypes and the abundance 
of recognition molecules on their cell surface (such as scavenging receptors, Fc receptors, 
and lectin receptors), macrophage-targeted NPs are highly customizable through surface 
functionalization by decoration with a desired ligand(s) (Mout, Moyano et al. 2012). A 
number of macrophage-targeted NPs have been developed for diagnostic imaging and 
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therapeutics. Nahrendorf and colleagues employed NP-mediated siRNA silencing of 
inflammatory monocyte migration across a variety of disease models. In these studies, 
the chemokine receptor CCR2, a critical receptor in monocyte recruitment and 
chemotaxis, was targeted by delivery of CCR2 siRNA using a lipid-like carrier (designated 
C12-200) that facilitates RNA interference at orders-of-magnitude lower doses than other 
siRNA delivery systems (Leuschner, Dutta et al. 2011). C12-200-CCR2 siRNA reduced 
trafficking of inflammatory monocytes to tissues of injury, including myocardial infarction, 
atherosclerosis, pancreatic islets after transplantation, and lymphoma/colorectal tumor 
xenografts; in all cases reducing indicators of disease. Though these studies did not utilize 
specific targeting of NPs to macrophages, further derivatization of similar NPs may 
optimize siRNA or drug delivery to macrophages. Mulder and colleagues have developed 
NPs that mimic, with the exception of an inorganic core, the natural nanoparticle high-
density lipoprotein (HDL) housing a payload (either contrast agents or pharmacological 
drug) (Cormode, Skajaa et al. 2008). These reconstituted HDL (rHDL)-NPs are derivatized 
through the presence of apolipoprotein A1 (ApoA1) in the phospholipid monolayer shell 
of the NPs. The preliminary studies in this Chapter explore the development of celecoxib, 
a selective COX-2 inhibitor, as a targeted nanomedicine. In collaboration with Drs 
Cormode, Mulder, and colleagues, HDL-NPs were loaded with celecoxib as a potential 
preventative or therapeutic measure for breast cancer. Successful development of 
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macrophage specific COX-2 inhibitor nanotherapy may provide the anti-tumor benefit 
while avoiding the cardiovascular side effects associated with global COX-2 inhibition. 
4.2 Experimental Procedures 
4.2.1 Generation of rHDL-DiR and rHDL-celecoxib Nanoparticles 
For incorporation of 1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine 
iodide (DiR), a near IR fluorescent dye, and celecoxib in rHDL nanoparticles: 1-myristoyl-
2-hydroxy-sn-glycero-phosphatidylcholine (MHPC) and 1,2-dimyristoyl-sn-glycero-3-
phosphatidylcholine (DMPC, Avanti Polar Lipids) are dissolved in chloroform/methanol 
(4:1) solvent, with or without DiR (Invitrogen) or celecoxib (Tocris Bioscience), and dried 
to form a thin film. Human apoA1 (CSL, Parkville, Australia) in PBS is added (2:1 ratio of 
drug to apo-A1) and the solution incubated at 37°C for hydration and formation of a 
homogenous solution. Following sonication to form small rHDL-DiR or rHDL-celecoxib (or 
control rHDL without drug) nanoparticles (schematic in Figure 4-1), aggregates are 
removed by centrifugation and filtration. Size and shape of the nanoparticles is confirmed 
by transmission electron microscopy and dynamic light scattering. Celecoxib loading is 
quantified by liquid chromatography/tandem mass spectrometry; apo-A1 levels are 
quantified by protein assay. We have successful generated rHDL-DiR and rHDL-celecoxib 
nanoparticles with efficient incorporation of dye and drug. Samples stored at 4°C for 
several 6-8 weeks were assayed using Vivaspin 500 columns with 100kDa cutoff (Sartorius  
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Figure 4-1 Schematic representations of rHDL and rHDL-celecoxib nanoparticles.  
rHDL-celecoxib nanoparticles are composed of recombinant human apo-A1 and the phospholipids 1-myristoyl-2-
hydroxy-sn-glycero-phosphocholine (MHPC) and 1,2-dimyristoyl-sn-glycero-3-phosphatidylcholine (DMPC) in which 
celecoxib is encapsulated. Reproduced with permission and modified (Duivenvoorden, Tang, et al 2013). 
Figure 4-2 Accumulation of rHDL-DiR in orthotopic tumors.  
Tumor bearing (NAFLuc) mice were injected with rHDL-DiR (1 mg/kg DiR, 0.7 mg/kg apo-A1) two weeks post-injection of 
tumor cells. DiR fluorescence colocalized with bioluminescence illustrating accumulation of rHDL-DiR in tumors. 
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Stedim Biotech) according to manufacturer’s protocol to investigate dissociation of rHDL-
celecoxib into free rHDL and free celecoxib. 
4.2.2 Animal Experiments 
For orthotopic injection of tumor cells, NAFLuc tumor cells were treated with 0.25% 
trypsin for 10 minutes. NAFLuc cells were resuspended at 1 x 107 cells/mL and injected into 
the left and right #4 mammary glands of FVB/N WT mice between 8-14 weeks of age 
(100µL/gland; 1 x 106 cells). Following two weeks of tumor growth, mice were 
intravenously injected with rHDL-DiR nanoparticles (1 mg/kg DiR, 0.7 mg/kg apo-A1). 24 
hours following injection, mice were scanned for fluorescence at 745 (30) nm excitation 
and 820 (20) nm emission in an IVIS Spectrum (Perkin Elmer). Following rHDL-DiR 
scanning, mice were intraperitoneally injected with 150 mg/kg D-Luciferin (Gold 
Biotechnology, #LUCK-100) dissolved in DPBS, and scanned 20 minutes post injection in 
an IVIS Spectrum for detection of bioluminescence. rHDL-celecoxib or empty rHDL 
(1.5mg/ml celecoxib, 0.8mg/ml apo-A1; control rHDL nanoparticles - 1.5mg/ml apo-A1) 
was intravenously injected into tumor free C57BL/6 mice. 18 hrs after injection, mice 
were stimulated with 1 mg/kg LPS. Urine was collected in metabolic cages following rHDL-
celecoxib injection. 6 hrs after LPS injection (24 hrs after rHDL-celecoxib injection), mice 
were euthanized and peritoneal macrophages collected, described below. 
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4.3.3 Cell Culture and Treatments 
Peritoneal macrophages were collected by injection of 10mL PBS into the 
peritoneal cavity and aspirated. Cells were pelleted, resuspended in 10% FBS/DMEM, and 
plated in a 10cm2 plate per mouse. J774A.1cells (American Type Cell Culture, #TIB-67) 
were cultured in 10% FBS/DMEM and split, when confluent, by gentle scraping. J774A.1 
cells were plated at approximately 1 x 106 cells per 10cm2 plate prior to treatment. 
J774A.1 cells and peritoneal macrophages were treated with celecoxib (5 μM), rHDL-
celecoxib (celecoxib 5 μM, apo-A1 1 μg/mL), or rHDL (1 μg/mL) for 18 hours prior to 
induction of prostaglandin synthesis with 5 μg/mL LPS. After 6 hrs, media was collected 
for prostaglandin measurement by LC-MRM-MS (described below). 
4.3.4 Mass Spectrometry, Flow Cytometry 
LC-MRM-MS detection of prostaglandins in cell culture media and urine and flow 
cytometry of tumor cells are described in Chapter 2. List of antibodies used is included in 
Table 2-1.  
4.3 Results 
4.3.1 Uptake of rHDL-DiR by Tumor-Associated Macrophages 
 DiR, a lipophilic near-infrared dye, is highly fluorescent when incorporated into 
cellular membranes. To confirm uptake of rHDL-DiR by macrophages, WT orthotopic 
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NAFLuc-tumor bearing mice were treated with rHDL-DiR via tail vein injection (1 mg/kg 
DiR, 0.7 mg/kg apo-A1) after two weeks of tumor growth. Twenty-four hours later, side-
by-side analysis of bioluminescent imaging (tumor) and fluorescence (rHDL-DiR; 745 nm) 
revealed accumulation of rHDL-DiR NPs in tumors (Figure 4-2). Tumors were digested to 
single cell suspensions and analyzed by flow cytometry. Approximately 10% of cells in the 
tumor were positive for DiR and, within the DiR+ population, approximately 40% were 
macrophages (CD11b+F4/80+; Figure 4-3A). Thus it is likely that rHDL-DiR was also taken 
up by other cells, possibly tumor cells or tumor endothelium. Very few macrophages were 
found in the DiR- population. Gating on macrophages, a majority of CD11b+F4/80+ cells 
showed DiR positivity (Figure 4-3B). Thus, TAMs accounted for a significant portion of 
rHDL-NP uptake, and the vast majority of TAMs were rHDL-NP positive. These studies 
confirmed the accumulation of rHDL-NPs in tumors through uptake by TAMs, as well as 
other cells in the tumor. 
4.3.2 Analysis of Macrophage COX-2 Inhibition by rHDL-Celecoxib Nanoparticles 
 To test stability of the rHDL-NPs, rHDL-celecoxib stored at 4°C for 6-8 weeks was 
passed through a Vivaspin column, which separates free celecoxib from rHDL-conjugated 
celecoxib, and analyzed by LC-MS/MS, revealing minimal dissociation of celecoxib from 
rHDL-celecoxib NPs (Figure 4-4). Preliminary analysis of rHDL-celecxoib were performed 
in J774 cells, a mouse monocyte-macrophage line, to establish efficacy for COX-2  
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Figure 4-4 rHDL-celecoxib is stable at 4°C for several weeks.  
rHDL-celecoxib nanoparticle solution after particle separation (100kDa cutoff) had minimal free celecoxib in 
flowthrough. Data are preliminary from one experiment (n=1). 
Figure 4-3 TAM uptake of rHDL-DiR by flow cytometry.  
(A) Approximately 40% of DiR+ cells in dissociated tumor cells were TAMs by flow cytometry. (B) The majority of TAM 
(CD11b+F4/80+) were positive for DiR. Data are preliminary from one experiment (n=1). 
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Figure 4-5 Production of prostaglandins in J774A.1 cells after rHDL-celecoxib treatment.  
Treatment with rHDL-celecoxib suppressed production of (A) PGD2 and (B) PGE2, and to a lesser extent, (C) PGI2 and (D) 
TxA2 metabolites in murine macrophage cell line J774A.1 to levels similar to suppression by celecoxib. Interestingly, 
rHDL also suppressed production of PGD2 and PGE2. Data are preliminary from one experiment (n=1). 
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Figure 4-6 Urinary production of prostaglandins in mice after rHDL-celecoxib treatment.  
No change in urinary prostaglandins was detected 24 hrs after treatment of WT mice with rHDL-celecoxib (1.5mg/ml 
celecoxib, 0.8mg/ml apo-A1; control rHDL nanoparticles - 1.5mg/ml apo-A1). Data are mean ± SEM, n=2. 
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Figure 4-7 Ex vivo cultured peritoneal macrophage production of prostaglandins is unchanged after rHDL-celecoxib 
treatment.  
Production of prostaglandins in isolated resident peritoneal macrophages treated with rHDL-celecoxib (24 hrs) and LPS 
(final 6 hrs) was decreased in 1 of 2 samples as compared to rHDL alone. Data are mean ± SEM, n=2. 
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inhibition. Pretreatment of J774A.1 cells with rHDL-celecoxib, with or without LPS 
stimulation, suppressed PGE2, PGD2, and TxA2 production and this was equivalent to 
treatment with free celecoxib (Figure 4-5). Interestingly, pretreatment with empty rHDL-
NPs also seemed to reduce prostanoid formation, though there was no additive effect of 
rHDL-celecoxib compared to unloaded rHDL plus free drug. To investigate the ability of 
rHDL-celecoxib to inhibit prostanoid formation in vivo, WT mice were injected, via tail 
vein, with rHDL or rHDL-celecoxib and, 18 hours later, injected with LPS intraperitoneally. 
Urinary prostaglandin metabolites were not different between rHDL and rHDL-celecoxib 
treatment (Figure 4-6), indicating that, as expected, rHDL-celecoxib did not modify 
systemic COX-2 function. Of particular relevance to this nanomedical approach to 
targeted COX-2 inhibition, urinary PGI2 metabolite levels, a measure of vascular 
endothelial COX-2 function and a surrogate for the thrombotic risk of systemic COX-2 
inhibition, were not reduced with rHDL-celecoxib. Resident peritoneal macrophages 
isolated from these mice showed minor alterations in prostanoid generation in rHDL-
celecoxib treated mice, as compared to rHDL alone (Figure 4-7), suggesting successful 
targeting of macrophage COX-2 by rHDL-celecoxib in vivo. However, the sample size in 
this preliminary experiment was small (n=2), and there was marked variability between 
samples. It may be, however, that rHDL-celecoxib NPs do not incorporate efficiently into 
peritoneal macrophages, as opposed to TAM or other macrophage subsets, or that 
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further optimization of rHDL-celecoxib NP will be necessary to efficiently deliver the drug 
to the desired target. Despite these caveats, these in vitro and in vivo data together are 
highly encouraging in that rHDL-celecoxib may allow targeted inhibition of COX-2 in TAM 
accumulation as a novel approach to reduce tumor growth. 
4.4 Discussion 
The preliminary studies in this Chapter illustrate a possible strategy of targeted 
macrophage COX-2 inhibition. Strong DiR fluorescence in tumors (Figure 4-2) represented 
uptake of rHDL-DiR by TAM, which made up approximately 40% of the DiR+ population 
within the tumor (Figure 4-3A). Further, a vast majority of TAM were DiR+, indicating 
robust uptake of the NP by the desired target cell (Figure 4-3B). Preliminary experiments 
investigating a novel rHDL-celexcoxib nanotherapeutic revealed efficient suppression of 
PGD2 and PGE2 in J774A.1 cells that was as effective as free celecoxib (Figure 4-5). 
Interestingly, rHDL also reduced generation of PGD2 and PGE2, though the effect of rHDL 
and celecoxib was not additive with rHDL-celecoxib. This may suggest suppression of COX-
2 function by rHDL alone although HDL is associated with enhanced COX-2 expression, 
particularly in endothelial cells in the context of atherosclerosis (Liu, Ji et al. 2012). 
Analysis of urine prostaglandins revealed no difference in concentration of prostaglandin 
metabolites, suggesting rHDL-celecoxib did not systemically inhibit COX-2 function (Figure 
4-6). Finally, analysis of elicited peritoneal macrophage cell culture supernatants revealed 
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minimal change in prostaglandin generation treated with rHDL-celecoxib, though a slight 
reduction was apparent (Figure 4-6). These studies are essential preliminary experiments 
in determining the feasibility of targeted therapies which specifically inhibit macrophage 
COX-2. 
Interestingly, in preliminary studies with in vivo rHDL-DiR uptake by tumor, a 
substantial proportion of cells positive for DiR were not TAM. It is likely, therefore, that 
cells other than TAM can incorporate rHDL-NPs, raising the possibility that, within the 
tumor at least, COX-2 inhibition may extend beyond macrophages. Indeed, the clear 
accumulation of rHDL-DiR in tumors (Figure 4-2), and the apparent uptake of NPs by cells 
other than TAM, may indicate that this approach both targets macrophages and provides 
for a general drug delivery method to tumors. This is likely to be a benefit, given the anti-
tumorigenic effect of MEC COX-2 deletion in HER2/neu-induced mammary tumorigenesis 
(see Chapter 1.2.5) and published studies that COX-2 in cancer-associated fibroblasts is 
also pro-tumorigenic (Vandoros, Konstantinopoulos et al. 2006). Although cell-by-cell 
analysis of COX-2 function in the TME has not been performed, the reduction in 
tumorigenesis seen with deletion of COX-2 from either MEC or macrophages, strongly 
suggests that uptake of rHDL-celecoxib by multiple cells within the tumor will enhance 
the therapeutic benefit. 
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Treatment of J774A.1 cells with rHDL-celecoxib resulted in a reduction of PGD2 
and PGE2 generation similar to those levels observed with free celecoxib. Thus rHDL-
celecoxib appeared to be as efficient in inhibiting COX-2 function as celecoxib. An 
alternative explanation, that celecoxib dissociates from rHDL-celecoxib and is free in 
solution, is unlikely - we confirmed, by LC/MS/MS, that the celecoxib remained 
incorporated in the rHDL-NP for several weeks at 4oC (Figure 4-4), and that free celecoxib 
in solution was vanishingly small. Notably, in mice treated with rHDL-celecoxib urinary 
prostaglandin metabolites were unchanged as compared to rHDL alone-treated mice, 
arguing against free celecoxib “leak” from the NPs and, as desired, against systemic COX-
2 inhibition with the nanotherapeutic approach. Our attempts to confirm targeted 
inhibition of macrophage COX-2 in vivo, using resident peritoneal macrophages, were 
inconclusive. Further, the published anti-inflammatory effect of rHDL (Sanson, Distel et 
al. 2013) may comparatively blunt suppression of prostaglandin synthesis by rHDL-
celecoxib in LPS-stimulated macrophages, requiring increased sample size to detect the 
effect or focused consideration of bone fide TAM rather than peritoneal macrophages as 
a surrogate. With increased numbers of mice, examination of additional macrophage 
populations, and dose finding studies, the discriminant impact of rHDL-celecoxib on 
macrophage COX-2 function with little or no systemic inhibition, may be confirmed. 
Based on our demonstration that macrophage COX-2 deletion reduced mammary 
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tumorigenesis, a goal of this Chapter was to establish the feasibility of targeted inhibition 
of macrophage COX-2. To this end, we chose a pharmacological approach, using celecoxib 
as a COX-2 inhibtior. As mentioned in Chapter 3, however, pharmacological inhibition may 
not fully recapitulate the phenotype observed by genetic deletion of the same target 
enzyme. Careful consideration of pharmacological versus genetic approaches, using rHDL-
celecoxib compared to siRNA-mediated knock-down of COX-2 expression (Leuschner, 
Dutta et al. 2011) will be important in moving this work forward. The studies outlined in 
this Chapter provide a useful first step in the development and utilization of a macrophage 
COX-2 targeted therapy. Indeed, the studies in this Thesis support a primary and 
ambitious objective to develop a chemopreventative or chemotherapeutic agent that 
provides the benefits of systemic COX-2 inhibition while avoiding the established 
cardiovascular adverse events related to their use. 
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CHAPTER 5 : DISCUSSION, FUTURE DIRECTIONS, AND PERSPECTIVE 
5.1 Conclusions and Discussion 
5.1.1 Deletion of Macrophage COX-2 Reduces Mammary Tumorigenesis 
To investigate the role of macrophage COX-2 in directing mammary 
tumorigenesis, we generated mice with selective deletion of COX-2 in a subset of myeloid-
derived cells, the primary effect of which is macrophage COX-2 deletion. In an MMTV-neu 
spontaneous model of mammary tumorigenesis, COX-2MØKOneu mice had delayed tumor 
onset, reduced tumor growth, and reduced tumor multiplicity at sacrifice as compared to 
WTneu mice (Figure 2-3). Reduced tumorigenesis in COX-2MØKOneu mice was recapitulated 
in an orthotopic model of MMTV-neu driven mammary tumorigenesis, with reduced SMF 
mammary tumor cell growth in COX-2MØKO host mice (Figure 2-9). Though no change was 
observed in apoptosis, proliferation or angiogenesis in either model, (Figure 2-4-7,10-13), 
enhanced TAM density and reduced T cell density was observed in COX-2MØKO host mice 
in the orthotopic model (Figure 2-14). Increased TAM was associated with reduced 
expression of CSF-1R (Figure 2-15), an important macrophage growth factor and 
chemokine, in COX-2MØKO BMDM. Further, COX-2MØKO BMDM had a reduced propensity 
to migrate towards CSF-1 or SMF tumor cell-conditioned medium (Figure 2-16). WT 
BMDM migration was ablated after treatment of SMF-CM with anti-CSF-1, indicating CSF-
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1 dependent migration. In addition to reduced migration by COX-2MØKO macrophages, 
COX-2MØKO TAM had reduced expression of M2 macrophage markers (Figure 2-17), 
suggesting that the increase in T cell density may be due to reduced overall TAM and M2-
like TAM, leading to a less immune suppressive TME in COX-2MØKO tumors. Although 
augmented T cells in COX-2MØKO tumors were associated with an increase in both CD4+ 
and CD8+ T cells, antibody-mediated depletion of CD4+ T cells did not alter tumor growth 
(Figure 2-20) while depletion of CD8+ CTLs enhanced tumor growth in COX-2MØKO mice 
to rates seen in WT host mice, indicating that deletion of macrophage COX-2 leads to 
enhanced CTL function which reduces tumorigenesis. 
We previously reported reduced mammary tumorigenesis after deletion of MEC 
COX-2, which led to enhanced CTL-mediated tumor suppression. As COX-2-derived PGE2 
is able to positively feed its own synthesis (Diaz-Munoz, Osma-Garcia et al. 2012), we 
acknowledge the possibility that deletion of TAM COX-2 may block a critical paracrine 
loop which induces tumor cell COX-2 expression. Indeed, COX-2 mRNA levels in COX-
2MØKO tumors were significantly reduced, suggesting suppression of COX-2 expression in 
cell types other than TAM (Figure 2-9C). However, reduced tumorigenesis in this model 
led to enhanced expression of T cell chemokines and a coincident reduction in PD-L1 
expression in tumors, while reduced tumorigenesis in COX-2MØKO mice is attributed to 
reduced expression of CSF-1R and M2-like immune suppressive function. Thus, we 
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suspect that macrophage and MEC COX-2 deletion mediate reduced mammary 
tumorigenesis by distinct mechanisms. We further highlight a lack of immune cell 
population changes in the spontaneous tumor model as compared to the orthotopic 
model in COX-2MØKO mice. Although the high variability of cell composition in the 
spontaneous model did not provide sufficient resolution to observe changes in TAM and 
T cell numbers, analysis of TAMs and CTLs by flow cytometry revealed a similar reduction 
in expression of M2 phenotypic markers in COX-2MØKOneu tumors and a negative 
correlation between TAM density and CTL function in WTneu tumors, suggesting that, 
similar to the orthotopic model, reduced tumorigenesis is mediated through fewer 
immunosuppressive TAM leading to enhanced CTL presence and function. Further, 
although we provide evidence for CTL-mediated tumor suppression in COX-2MØKO mice, 
cytolytic functions of CTLs are typically attributed to induction of apoptosis, and we 
observed no change in cell turnover in either the spontaneous or orthotopic model. We 
suggest the possibility that divergent expression of apoptosis marker caspase 3 by 
different cell types may explain the lack of difference in its expression, whereby 
hypothetical increases in tumor cell apoptosis in COX-2MØKO mice is blunted by high T cell 
apoptosis in WT mice. Alternatively, caspase-independent mechanisms of CTL-mediated 
apoptosis exist (Trapani, Jans et al. 1998, Beresford, Xia et al. 1999).  
 These studies highlight an essential function of macrophage COX-2 in modifying 
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TAM phenotype and macrophage infiltration of tumors, leading to enhanced CTL-
mediated tumor suppression. Thus, targeted macrophage COX-2 inhibition may be a 
potential avenue in enhancing tumor suppressive immunosurveillance, which could 
provide the anti-tumor benefits of COX-2 inhibition without the off-target adverse effects 
associated with systemic inhibition. 
5.1.2 Paracrine and Autocrine COX-2 Contribute to Macrophage Polarization 
M1 polarization of BMDM led to strong induction of COX-2 and mPGES-1 gene 
expression with suppression of COX-1 and 15-PGDH (Figure 3-1), while M2 polarization 
slightly induced COX-1 expression and reduced COX-2 and 15-PGDH expression. 
Interestingly, the addition of exogenous PGE2 to M2 polarized BMDM led to restored or 
enhanced COX-2 and mPGES-1 expression, respectively (Figure 3-3). mPGES-1 expression 
in M1 polarized BMDM was similarly enhanced with PGE2, while COX-2 expression was 
sustained. Taken together, these studies revealed strong modification of COX pathway 
enzyme and transporter expression and a role of paracrine PGE2 in further altering gene 
expression. In agreement with reports of reduced inflammatory characteristics of PGE2-
treated macrophages, expression of M1 macrophage markers TNFα, IL-6, and CD86 were 
reduced with addition of exogenous PGE2 to M1 polarized BMDM (Figure 3-5). 
Interestingly, expression of the M2 macrophage marker arginase-1 was dose-dependently 
augmented after PGE2 treatment under both M1 and M2 polarizing conditions (Figure 3-
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5,6). Experiments investigating the effect of macrophage COX-2 deletion revealed no 
changes in gene expression of COX pathway enzymes and transporters in M1 or M2 
polarized COX-2MØKO BMDM, aside from a reduction in M1-induced COX-2 expression 
(Figure 3-8,9). Also, treatment of COX-2MØKO BMDM with selective COX-2 inhibitor 
rofecoxib further suppressed COX-2 expression, suggesting residual COX-2 after genetic 
deletion. Analysis of M1 and M2 phenotypic markers did not suggest any consistent 
changes in macrophage phenotype due to genetic COX-2 deletion or pharmacological 
inhibition of COX-2. 
TAM in breast cancer are typically classified as M2-like, but have a unique 
phenotype that is not characteristically identical to either M1 or M2 macrophages. PGE2-
mediated suppression of M1 markers TNFα and IL-6 in M1 polarized macrophages 
recapitulate observations that PGE2 can suppress LPS-induced inflammatory cytokine 
production (Chen and Smyth 2011). Induction of PGE2-induced arginase-1 expression 
under both M1 and M2 polarizing conditions illustrate the ability of PGE2 to augment 
immunosuppressive characteristics of TAM. Interestingly, sufficient expression of COX-2 
in TAM does not mirror severely suppressed COX-2 expression after M2 polarization. 
However, treatment of M2 polarized macrophage with PGE2 restored COX-2 expression 
to levels seen prior to M2 polarization. Thus, we suggest that PGE2 is able to condition 
BMDM to have a TAM-like phenotype, regardless of polarization condition, in which low 
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expression of M1 cytokines, high expression of arginase-1, and sufficient expression of 
COX-2 are TAM-like characteristics. As macrophage deletion resulted in reduced 
expression of M2 macrophage marker expression in TAM, it was unexpected that COX-
2MØKO BMDM did not have an altered M1 or M2 macrophage phenotype profile as 
compared to WT BMDM. Comparison between polarized BMDM, which are matured in 
vitro, and TAM, which are constantly under the influence of the TME, may not be ideal, 
and these studies may caution against application of in vitro phenotypes to in vivo 
settings. 
These studies illustrate a role of paracrine COX-2-derived products in altering 
macrophage phenotype in vitro, and further suggest that PGE2 is the primary 
prostaglandin mediator responsible for augmented M2 phenotype in macrophages. 
Further, BMDMs, at least in vitro, are able to polarize to the M1 and M2 macrophage 
phenotype with sufficient expression of M1 and M2 phenotypic markers, regardless of 
autocrine COX-2 expression. Analysis of the effect of COX-2-derived products on BMDM 
polarization allows the assessment on whether in vitro polarization of macrophages is 
useful as a model of macrophage phenotype in disease models. 
5.1.3 rHDL-Celecoxib as a Potential Macrophage COX-2 Targeted Therapy 
rHDL containing DiR, a fluorescent dye, accumulated in NAFLuc tumors (Figure 4-
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2). Flow cytometry of dissociated tumor cells revealed that 40% of the DiR positive 
population in tumors were TAMs. Further, gating on TAMs revealed that the vast majority 
of TAMs were DiR+ (Figure 4-3). Thus, while TAM show efficient uptake of rHDL-DiR 
nanoparticles, other cells in the tumor also incorporate rHDL-DiR. Following 
demonstration of incorporation of rHDL-NPs into TAM, we developed rHDL-celecoxib NPs 
and tested their incorporation in vitro with the murine macrophage cell line J774A.1. In 
preliminary experiments, rHDL-celecoxib suppressed LPS-mediated induction of 
prostaglandin synthesis to levels similar to celecoxib alone (Figure 4-4). Interestingly, 
rHDL alone also reduced prostaglandin synthesis, suggesting anti-inflammatory effects of 
rHDL. Further, IV injection of rHDL-celecoxib into WT mice did not reduce urine 
concentrations of prostaglandins, indicating no systemic inhibition of COX-2 (Figure 4-5). 
Sufficient macrophage COX-2 inhibition in isolated and ex vivo cultured peritoneal 
macrophages isolated from rHDL-celecoxib treated mice was inconclusive due to the 
small sample size (Figure 4-6). These studies suggest that further experimentation is 
required for the development and validation of a macrophage COX-2 targeted therapy. 
 Based on J774A.1 experiments in which rHDL-celecoxib suppressed prostaglandin 
formation to levels similar to that of celecoxib, a potential concern of these experiments 
may be that rHDL-celecoxib dissociates in cell culture or acts in a similar fashion as free 
celecoxib. Importantly, analysis of urine prostaglandins revealed no systemic inhibition of 
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COX-2, arguing against dissociation of rHDL-celecoxib NPs in circulation. A secondary 
concern, arising from lack of COX-2 inhibition in peritoneal macrophages cultured ex vivo, 
may be that rHDL-NPs do not incorporate with macrophages in vivo. However, based on 
imaging studies using rHDL-DiR NPs in which TAM showed clear incorporation of DiR, we 
consider this unlikely. Thus, further experiments investing rHDL-celecoxib mediated COX-
2 inhibition will be required, and, if warranted, further optimization of the targeted NP. 
 These studies provide essential first steps in determining the feasibility in the 
development and use of a targeted macrophage COX-2 inhibitor in the treatment of 
breast cancer. Successful identification of a chemopreventative or chemotherapeutic 
COX-2 inhibitor which reduces mammary tumorigenesis while avoiding the adverse 
effects associated with systemic COX-2 inhibition may be an attractive treatment in breast 
cancer. 
5.2 Future Directions 
Macrophage COX-2 deletion led to reduced tumorigenesis through reduced M2-
like and total TAM, enhancing CTL-mediated tumor suppression. Further investigation of 
the effect of macrophage COX-2 deletion would include additional analysis on how COX-
2MØKO macrophages and T cells interact. A co-culture system in which naïve splenic T cells 
are grown in the presence of WT or COX-2MØKO TAM or BMDM may support altered T cell 
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function due to loss of macrophage COX-2. One particular concern of these studies in 
Chapter 2 is the effect of COX-2 KO in other myeloid-derived cells that may alter 
tumorigenesis. To definitively attribute reduced tumorigenesis to KO of COX-2 in 
macrophages, adoptive transfer of WT macrophages into tumor-bearing COX-2MØKO 
animals could be performed. Restoration of tumor growth after transfer of WT 
macrophages would suggest that deletion of COX-2 in macrophages is the primary driver 
behind reduced tumorigenesis. Reduced disease in both COX-2MØKO and COX-2MECKO 
mice may suggest that an additive effect could be achieved through dual KO of 
macrophage and MEC COX-2. Although studies observing similar reductions in mammary 
tumorigenesis from COX-2MECKO mice and rofecoxib-treated mice may argue against an 
additive effect (Markosyan, Chen et al. 2011), dual KO of macrophage and MEC COX-2 
may act through a different mechanism or have less off-target effect compared to 
systemic COX-2 inhibition. 
The models of mouse mammary tumorigenesis described in Chapter 2 grow large, 
aggressive primary tumors and are not suitable for analysis of distant tumor events, such 
as metastatic disease. Additionally, models of primary tumor mastectomy and tumor 
recurrence (Sarkisian, Keister et al. 2007) are possible and would provide additional 
information concerning the usefulness of a targeted macrophage COX-2 inhibitor. 
Analysis of COX-2MØKO mice in these models would be interesting, as macrophages have 
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a well-known influence on metastatic disease (Pollard 2004, Lin, Li et al. 2006) and COX-
2 inhibition has been associated with reduced risk of distant recurrence. Further, due to 
advances in early detection and improved surgical lumpectomy, breast cancer patients 
rarely succumb to primary disease, and, instead, mortality is caused by distant metastases 
or resistant recurrent tumors. Additionally, TAMs have distinct roles in cancers other than 
breast cancer, and even within breast cancer, multiple types of disease exist. Indeed, anti-
CTLA4 treatment has had the most success in the clinic in treating metastatic melanoma, 
suggesting that a targeted macrophage COX-2 inhibitor as a potential treatment option 
may be useful in cancers other than HER2/neu-induced breast cancer. This may suggest 
the investigation of COX-2MØKO mice in additional models of breast and other cancers. 
Experiments studying M1 and M2 macrophage polarization suggested that PGE2 
acts as a paracrine mediator in determining macrophage polarization. It would be 
interesting to investigate whether simultaneous culture of SMF and NAF mammary tumor 
cell lines would similarly alter macrophage polarization such that BMDM would have a 
TAM-like phenotype. Further, considering that in vitro polarization of COX-2MØKO BMDM 
did not seem to recapitulate changes in TAM phenotype observed in both spontaneous 
and orthotopic tumors, it would be interesting to investigate macrophage polarization in 
the context of TAM instead of BMDM. These experiments would use isolated COX-2MØKO 
and WT TAM, cultured ex vivo, to investigate macrophage polarization. 
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Preliminary experiments utilizing rHDL-NPs illustrated accumulation of 
nanoparticles in tumor. rHDL-celecoxib efficiently incorporated with J774A.1 cells in vitro 
and revealed no change in systemic COX-2 function, but minimally altered peritoneal 
macrophage production of prostaglandins. Increased sample size in these studies will be 
required to establish successful inhibition of macrophage COX-2 by these NPs, which may 
require further optimization before their use in vivo. Once optimized, rHDL-celecoxib may 
be a method of inhibiting macrophage COX-2 in models of mammary tumorigenesis as 
described in previous chapters. If these studies are able to recapitulate the reduced 
tumorigenesis observed in COX-2MØKO mice, rHDL-celecoxib may be a promising potential 
therapy in the treatment of breast cancer. 
5.3 Perspective and Summary 
The studies in this Thesis were focused toward an ultimate goal of bringing new 
avenues of therapy into the clinic for the treatment of breast cancer. Translational cancer 
research is the application of basic research findings from models of tumorigenesis to 
human disease, with the intent of expediting discovery of medical devices, therapeutics, 
or diagnostic assays to benefit public health. Indeed, though animal models of 
macrophage COX-2 deletion reduced tumor onset and tumor growth, development of a 
therapeutic is necessary for successful translation of these findings for human cancer 
therapy. Thus, we developed rHDL-celecoxib as a macrophage targeted COX-2 inhibitor 
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with the intent of recapitulating reduced tumorigenesis observed by macrophage COX-2 
deletion in mice. Early experiments with HDL-celecoxib are promising, showing inhibition 
of COX-2 in vitro with no reduction in systemic COX-2 after IV infusion in WT mice, though 
further experiments testing of macrophage COX-2 inhibition in vivo must be performed.  
Successful treatment of cancer in clinical trials is typically assessed with endpoints 
such as progression free survival, after surgery, radiation therapy, and/or standard of care 
chemotherapy, and percent change in tumor size, reflecting a requirement of newly 
discovered therapeutics to delay recurrent tumor growth or induce tumor regression. 
Thus, even if rHDL-celecoxib provides a reduction in tumor growth, as observed in both 
the spontaneous and orthotopic model by macrophage COX-2 deletion, this may not be 
sufficient to justify its use as a chemotherapeutic agent. Indeed, monotherapies have 
generally been ineffective in cancer treatment, and thus discovery of the correct 
combination of therapeutics that induces tumor regression may be required before 
bringing a targeted macrophage COX-2 inhibitor into humans. Alternatively, delayed 
tumor onset in COX-2MØKO mice may provide rationale for the use of targeted 
macrophage COX-2 inhibitors as a prophylactic treatment for prevention of either primary 
breast cancer or breast cancer recurrence. However, because rHDL-celecoxib NPs are 
given as an infusion, their application would require identification of high-risk, or highly 
responsive, individuals to justify intravenous nanomedicine delivery. Further, 
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demonstration of low adverse effects would be necessary to justify regular treatment 
with rHDL-celecoxib NPs. 
Although anti-CTLA4 and anti-PD-L1 have been successful in treating certain 
cancers, a number of challenges exist in treating tumorigenesis with immune-based 
therapies. One example of these challenges is the likelihood of patients to have already 
undergone standard of care for their cancer, including chemotherapy, prior to 
recruitment as a subject in a clinical trial in which an immune altering therapeutic is 
employed. In this instance, chemotherapy may have suppressed systemic immunity in 
subjects, which may cause failure of induction of an anti-tumor immune response. These 
challenges, and others, will need to be addressed as additional chemotherapies targeting 
the TME enter the clinic. 
This thesis explored the role of macrophage COX-2 in influencing mammary 
tumorigenesis through a mouse model of macrophage COX-2 deletion. These studies 
provide a roadmap for the rationale, development, and validation of macrophage COX-2 
inhibitors for use as a chemopreventative or chemotherapeutic agent. Successful 
development of a macrophage COX-2 inhibitor may provide the anti-tumor benefits of 
COX-2 inhibitors while avoiding the deleterious cardiovascular side effects associated 
with their use. Such a drug, in combination with other therapies, may provide a new 
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avenue of therapy in the treatment of breast cancer. 
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